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Summary of findings {#CD006404-sec1-0001}
===================

Summary of findings for the main comparisonPyronaridine‐artesunate (PY‐AS) compared to artemether‐lumefantrine (AL) for adults and children with uncomplicated *Plasmodium falciparum* malaria**Pyronaridine‐artesunate (PY‐AS) compared to artemether‐lumefantrine (AL) for adults and children with uncomplicated *Plasmodium falciparum* malariaPatient or population:** adults and children with uncomplicated *P falciparum* malaria **Setting:** malaria transmission settings **Intervention:** pyronaridine‐artesunate (PY‐AS) **Comparison:** artemether‐lumefantrine (AL)**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)№ of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with ALRisk with PY‐AS**Total failure: day 28 (PCR‐adjusted)15 per 1000**9 per 1000** (4 to 19)**RR 0.59** (0.26 to 1.31)3068 (4 RCTs)⊕⊕⊝⊝ **LOW**^a,b,c^\
*Due to indirectness and imprecision*Compared to AL, PY‐AS may have fewer PCR‐adjusted failures at day 28.Total failure: day 42 (PCR‐adjusted)23 per 1000**20 per 1000** (12 to 35)**RR 0.86** (0.49 to 1.51)2575 (4 RCTs)⊕⊕⊝⊝ **LOW**^a,b^\
*Due to indirectness and imprecision*There may be little or no difference in PCR‐adjusted failures at day 42 between PY‐AS and AL.Total failure: day 28 (unadjusted)126 per 1000**34 per 1000** (16 to 73)**RR 0.27** (0.13 to 0.58)3149 (4 RCTs)⊕⊕⊝⊝ **LOW**^a,d,e^\
*Due to indirectness and inconsistency*Compared to AL, PY‐AS may have fewer unadjusted failures at day 28.Total failure: day 42 (unadjusted)254 per 1000**155 per 1000** (117 to 208)**RR 0.61** (0.46 to 0.82)3080 (4 RCTs)⊕⊕⊝⊝ **LOW**^a,d,e^\
*Due to indirectness and inconsistency*Compared to AL, PY‐AS may have fewer unadjusted failures at day 42.Serious adverse events (42 days)3 per 1000**3 per 1000** (1 to 12)**RR 0.90** (0.19 to 4.22)2004 (3 RCTs)⊕⊕⊝⊝ **LOW**^f^\
*Due to imprecision*We do not know if there is a difference in serious adverse events between PY‐AS and AL.First treatment, ALT increase \> 5 × ULN (42 days)3 per 1000**9 per 1000** (3 to 22)**RR 2.92** (1.15 to 7.41)3341 (4 RCTs)⊕⊕⊝⊝ **LOW**^a,g^\
*Due to indirectness and imprecision*Compared to AL, PY‐AS may lead to higher events of ALT increase \> 5 × ULN. (Aggregate analysis indicates this estimate may be accurate).First treatment, AST increase \> 5 × ULN (42 days)4 per 1000**9 per 1000** (3 to 23)**RR 2.20** (0.83 to 5.82)3327 (4 RCTs)⊕⊝⊝⊝ **VERY LOW**^a,b,h^\
*Due to indirectness, inconsistency, and imprecision*We do not know if there is a difference in AST between PY‐AS and AL.First treatment, bilirubin increase \> 2.5 × ULN (42 days)6 per 1000**5 per 1000** (2 to 12)**RR 0.82** (0.33 to 2.04)3130 (3 RCTs)⊕⊕⊝⊝ **LOW**^a,b^\
*Due to indirectness and imprecision*We do not know if there is a difference in bilirubin between PY‐AS and AL.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: AL:** artemether‐lumefantrine;**ALT:** alanine aminotransferase; **AST:** aspartate transaminase; **CI:** confidence interval; **PCR**: polymerase chain reaction; **PY‐AS**: pyronaridine‐artesunate; **RCT**: randomized controlled trial; **RR:** risk ratio; **ULN**: upper limit of normal**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^2]

Summary of findings 2Pyronaridine‐artesunate (PY‐AS) compared to artesunate‐amodiaquine (AS‐AQ) for adults and children with uncomplicated *Plasmodium falciparum* malaria**Pyronaridine‐artesunate (PY‐AS) compared to artesunate‐amodiaquine (AS‐AQ) for adults and children with uncomplicated *Plasmodium falciparum* malariaPatient or population:** adults and children with uncomplicated *P falciparum* malaria **Setting:** malaria transmission settings **Intervention:** pyronaridine‐artesunate (PY‐AS) **Comparison:** artesunate‐amodiaquine (AS‐AQ)**Outcomes^a^Anticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)№ of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with artesunate‐amodiaquine (AS‐AQ)Risk with pyronaridine‐artesunate (PY‐AS)**Total failure: day 28 (PCR‐adjusted)8 per 1000**4 per 1000** (1 to 22)**RR 0.55** (0.11 to 2.77)1245 (1 RCT)⊕⊕⊝⊝ **LOW**^b,c^\
*Due to indirectness and imprecision*Compared to AS‐AQ, PY‐AS may have fewer PCR‐adjusted failures at day 28.Total failure: day 42 (PCR‐adjusted)6 per 1000**5 per 1000** (1 to 27)**RR 0.98** (0.20 to 4.83)1091 (1 RCT)⊕⊕⊝⊝ **LOW**^b,d^\
*Due to indirectness and imprecision*There may be little or no difference in PCR‐adjusted failures at day 42 between PY‐AS and AS‐AQ.Total failure: day 28 (unadjusted)75 per 1000**37 per 1000** (22 to 61)**RR 0.49** (0.30 to 0.81)1257 (1 RCT)⊕⊕⊕⊝ **MODERATE**^b^\
*Due to indirectness*Compared to AS‐AQ, PY‐AS probably has fewer unadjusted failures at day 28.Total failure: day 42 (unadjusted)195 per 1000**192 per 1000** (152 to 240)**RR 0.98** (0.78 to 1.23)1235 (1 RCT)⊕⊕⊕⊝ **MODERATE**^b^\
*Due to indirectness*There is probably little or no difference in unadjusted failures at day 42 between PY‐AS and AS‐AQ.First treatment, ALT increase \> 5 × ULN (42 days)1 per 1000**1 per** 1000 (0 to 7)**RR 1.41** (0.28 to 7.09)1317 (1 RCT)⊕⊕⊝⊝ **LOW**^b,e^\
*Due to indirectness and imprecision*Compared to AL, PY‐AS may have lead to higher events of ALT increase \> 5 × ULN. (Aggregate analysis indicates this estimate may be accurate).First treatment, AST increase \> 5 × ULN (42 days)4 per 1000**2 per** 1000 (0 to 8)**RR 0.43** (0.08 to 2.07)1317 (1 RCT)⊕⊝⊝⊝ **VERY LOW**^b,f^\
*Due to indirectness and imprecision*We do not know if there is a difference in AST between PY‐AS and AS‐AQ.First treatment, bilirubin increase \> 2.5 × ULN (42 days)1 per 1000**1 per** 1000 (0 to 16)**RR 0.99** (0.06 to 15.76)1317 (1 RCT)⊕⊝⊝⊝ **VERY LOW**^b,f^\
*Due to indirectness and imprecision*We do not know if there is a difference in bilirubin between PY‐AS and AS‐AQ.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: ALT:** alanine aminotransferase; **AS‐AQ**: artesunate‐amodiaquine; **AST:** aspartate transaminase; **CI:** confidence interval; **PCR**: polymerase chain reaction; **PY‐AS**: pyronaridine‐artesunate; **RCT**: randomized controlled trial; **RR:** risk ratio; **ULN**: upper limit of normal**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^3]

Summary of findings 3Pyronaridine‐artesunate (PY‐AS) compared to mefloquine plus artesunate (MQ+AS) for adults and children with uncomplicated *Plasmodium falciparum* malaria**Pyronaridine‐artesunate (PY‐AS) compared to mefloquine plus artesunate (MQ+AS) for adults and children with uncomplicated *Plasmodium falciparum* malariaPatient or population:** adults and children with uncomplicated *P falciparum* malaria **Setting:** malaria transmission settings **Intervention:** pyronaridine‐artesunate (PY‐AS) **Comparison:** mefloquine plus artesunate (MQ+AS)**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)№ of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with mefloquine plus artesunate (MQ+AS)Risk with pyronaridine‐artesunate (PY‐AS)**Total failure: day 28 (PCR‐adjusted)22 per 1000**8 per 1000** (3 to 23)**RR 0.37** (0.13 to 1.05)1117 (1 RCT)⊕⊕⊝⊝ **LOW**^a,b,c^\
*Due to indirectness and imprecision*Compared to MQ+AS, PY‐AS may have fewer PCR‐adjusted failures at day 28.Total failure: day 42 (PCR‐adjusted)29 per 1000**53 per 1000** (27 to 105)**RR 1.80** (0.90 to 3.57)1037 (1 RCT)⊕⊕⊝⊝ **LOW**^a,b^\
*Due to indirectness and imprecision*Compared to MQ+AS, PY‐AS may have more PCR‐adjusted failures at day 42.Total failure: day 28 (unadjusted)41 per 1000**15 per 1000** (7 to 32)**RR 0.36** (0.17 to 0.78)1120 (1 RCT)⊕⊕⊕⊝ **MODERATE**^a^\
*Due to indirectness*Compared to MQ+AS, PY‐AS probably has fewer unadjusted failures at day 28.Total failure: day 42 (unadjusted)83 per 1000**70 per 1000** (45 to 109)**RR 0.84** (0.54 to 1.31)1059 (1 RCT)⊕⊕⊝⊝ **LOW**^a,b,d^\
*Due to indirectness and imprecision*There is probably little or no difference in unadjusted failures at day 42 between PY‐AS and MQ+AS.Serious adverse events (42 days)7 per 1000**7 per 1000** (2 to 28)**RR 1.00** (0.25 to 3.97)1271 (1 RCT)⊕⊕⊝⊝ **LOW**^a,b^\
*Due to indirectness and imprecision*There may be little or no difference in serious adverse events between PY‐AS and MQ+ASFirst treatment, ALT increase \> 5 × ULN (42 days)2 per 1000**18 per 1000** (2 to 133)**RR 7.48** (0.99 to 56.45)1271 (1 RCT)⊕⊕⊝⊝ **LOW**^a,e^\
*Due to indirectness and imprecision*Compared to MQ+AS, PY‐AS may lead to higher events of ALT increase \> 5 × ULN. (Aggregate analysis indicates this estimate may be accurate).First treatment, AST increase \> 5 × ULN (42 days)0 per 1000**0 per 1000** (0 to 0)**RR 9.49** (0.55 to 162.64)1271 (1 RCT)⊕⊝⊝⊝ **VERY LOW**^a,f^\
*Due to indirectness and imprecision*We do not know if there is a difference in AST between PY‐AS and MQ+AS.First treatment, bilirubin increase \> 2.5 × ULN (42 days)2 per 1000**8 per 1000** (1 to 67)**RR 3.49** (0.43 to 28.29)1271 (1 RCT)⊕⊝⊝⊝ **VERY LOW**^a,f^\
*Due to indirectness and imprecision*We do not know if there is a difference in bilirubin between PY‐AS and MQ+AS.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: ALT:** alanine aminotransferase; **AST:** aspartate transaminase; **CI:** confidence interval; **MQ+AS**: mefloquine plus artesunate; **PCR**: polymerase chain reaction; **PY‐AS**: pyronaridine‐artesunate; **RCT**: randomized controlled trial; **RR:** risk ratio; **ULN**: upper limit of normal**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^4]

Summary of findings 4Pyronaridine‐artesunate (PY‐AS) compared to other antimalarials for adults and children with uncomplicated malaria**Pyronaridine‐artesunate (PY‐AS) compared to other antimalarials for adults and children with uncomplicated malariaPatient or population:** adults and children with uncomplicated malaria **Setting:** high and low transmission settings for *P falciparum* and *P vivax* malaria **Intervention:** pyronaridine‐artesunate (PY‐AS) **Comparison:** other antimalarials**Outcomes^a,b,c^Anticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)№ of participants (trials)Certainty of the evidence (GRADE)CommentsRisk with other antimalarialsRisk with pyronaridine‐artesunate (PY‐AS)**Serious adverse events5 per 1000**7 per 1000** (3 to 15)**RR 1.24** (0.54 to 2.84)3941 (7 RCTs)⊕⊕⊕⊝ **MODERATE**^d^\
*Due to imprecision*There was probably little or no difference in the rate of serious adverse events with PY‐AS compared to other antimalarials.First treatment, ALT increase \> 5 × ULN2 per 1000**7 per 1000** (3 to 14)**RR 3.34** (1.63 to 6.84)6614 (8 RCTs)⊕⊕⊕⊕ **HIGH**^e^ALT increase \> 5 × ULN is more frequent with PY‐AS compared to other antimalarials.First treatment, AST increase \> 5 × ULN3 per 1000**5 per 1000** (3 to 11)**RR 1.80** (0.89 to 3.65)6614 (8 RCTs)⊕⊕⊕⊝ **MODERATE**^f^\
*Due to imprecision*There is probably a small increased risk of AST increase \> 5 × ULN with PY‐AS compared to other antimalarials.First treatment, bilirubin increase \> 2.5 × ULN4 per 1000**4 per 1000** (2 to 9)**RR 1.03** (0.49 to 2.18)6417 (7 RCTs)⊕⊕⊕⊝ **MODERATE**^d^\
*Due to imprecision*There is probably little or no difference for bilirubin between PY‐AS and other antimalarials.Subsequent treatment(s), ALT \> 5 × ULN4 per 1000**8 per 1000** (3 to 23)**RR 2.18** (0.76 to 6.27)1649 (1 RCT)⊕⊕⊝⊝ **LOW**^d,f^\
*Due to imprecision and indirectness*There may be an increased risk of raised ALT with subsequent treatments with PY‐AS compared to other antimalarials.Subsequent treatment(s), AST \> 5 × ULN6 per 1000**11 per 1000** (4 to 27)**RR 1.82** (0.74 to 4.44)1649 (1 RCT)⊕⊕⊝⊝ **LOW**^d,f^\
*Due to imprecision and indirectness*There may be an increased risk of raised AST with subsequent treatments with PY‐AS compared to other antimalarials.Subsequent treatment(s), bilirubin \> 5 × ULN8 per 1000**9 per 1000** (3 to 24)**RR 1.13** (0.42 to 3.01)1649 (1 RCT)⊕⊕⊝⊝ **LOW**^d,f^\
*Due to imprecision and indirectness*There may be little or no difference for bilirubin between PY‐AS and other antimalarials.\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: ALT:** alanine aminotransferase; **AST:** aspartate transaminase; **CI:** confidence interval; **PY‐AS**: pyronaridine‐artesunate; **RCT**: randomized controlled trial; **RR:** risk ratio; **ULN**: upper limit of normal**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^5]

Background {#CD006404-sec1-0002}
==========

Description of the condition {#CD006404-sec2-0001}
----------------------------

Malaria poses a global health challenge, with an estimated 216 million cases and 445,000 deaths in 2016. *Plasmodium falciparum* (*P falciparum*) is the most important species of malaria, causing 99% of malaria cases in the World Health Organization (WHO) Africa region, and 66% in the South‐East Asia region ([@CD006404-bbs2-0063]).

The WHO defines uncomplicated malaria by the absence of clinical features of severe malaria, in the presence of an asexual *P falciparum* parasitaemia ([@CD006404-bbs2-0062]). Severe malaria is *P falciparum* parasitaemia with one or more of: impaired consciousness, prostration, multiple convulsions, acidosis, hypoglycaemia, severe malarial anaemia, renal impairment, jaundice, pulmonary oedema, significant bleeding, shock, raised lactate, or a parasitaemia of greater than 10%. If untreated, uncomplicated malaria can develop into severe malaria.

The WHO has recommended artemisinin‐based combination therapies (ACTs) as first‐line treatment of uncomplicated *P falciparum* malaria since 2006, recognising the risk of resistance with monotherapy ([@CD006404-bbs2-0059]). Artemisinin resistance has emerged in South‐East Asia, initially from the Thai‐Cambodian border, and has since become prevalent in Laos, Myanmar, Thailand, and Vietnam ([@CD006404-bbs2-0034]; [@CD006404-bbs2-0049]). This resistance remains a key concern, as further spread of artemisinin resistance could lead to high mortality ([@CD006404-bbs2-0043]). These concerns have led to global initiatives to contain the spread of artemisinin resistance, which includes the development of new drugs to partner and protect the artemisinin derivatives in ACT ([@CD006404-bbs2-0061]).

Description of the intervention {#CD006404-sec2-0002}
-------------------------------

The WHO currently recommends the following five ACTs for first‐line treatment of malaria.

Artemether‐lumefantrineArtesunate‐amodiaquineArtesunate‐mefloquineArtesunate‐sulphadoxine‐pyrimethamineDihydroartemisinin‐piperaquine

The artemisinin in ACTs rapidly clears parasites from the blood. It also kills some sexual forms of the parasite, and may reduce onward transmission to mosquitoes. The longer‐acting partner drug clears residual infections, and protects against resistance to artemisinin ([@CD006404-bbs2-0062]). Drug combinations with long half‐lives (artesunate‐mefloquine and dihydroartemisinin‐piperaquine) can provide a period of post‐treatment prophylaxis which may last for up to six weeks ([@CD006404-bbs2-0056]).

Pyronaridine is a potential partner drug for artesunate. Researchers in China developed pyronaridine during the mid‐1970s, using the nucleus of an earlier antimalarial compound (mepacrine) with an added amodiaquine side‐chain ([@CD006404-bbs2-0037]). Clinicians thereafter used pyronaridine extensively as monotherapy for *P falciparum* and *P vivax* infections in China ([@CD006404-bbs2-0031]). Concerns about observed in vitro resistance to pyronaridine lead Chinese researchers to use pyronaridine in combinations with sulphadoxine and pyrimethamine, and primaquine ([@CD006404-bbs2-0037]).

A public‐private partnership including the Medicines for Malaria Venture (MMV) and Shin Poong Pharmaceuticals Incorporated developed pyronaridine‐artesunate in combination from 2002 onwards ([@CD006404-bbs2-0045]), with its first national registration in 2011 (with the Korean Food and Drug Administration). For uncomplicated malaria, the treatment is taken once‐daily for three days. Treatment is provided as tablets for adults and children over 20 kg, or in granules for children and infants between 5 kg and 20 kg.

How the intervention might work {#CD006404-sec2-0003}
-------------------------------

The mode of action of pyronaridine is unclear, with several possible mechanisms ([@CD006404-bbs2-0033]). Pyronaridine has been shown to have potent in vitro activity versus *P falciparum* ([@CD006404-bbs2-0029]; [@CD006404-bbs2-0031]; [@CD006404-bbs2-0032]; [@CD006404-bbs2-0051]; [@CD006404-bbs2-0054]), even in strains with resistance to other antimalarials, including chloroquine, cycloguanil, amodiaquine, and sulfadoxine‐pyrimethamine ([@CD006404-bbs2-0030]; [@CD006404-bbs2-0040]; [@CD006404-bbs2-0052]). In vitro studies also indicate synergy between pyronaridine and artesunate versus parasites which are resistant to either agent ([@CD006404-bbs2-0050]; [@CD006404-bbs2-0057]).

Why it is important to do this review {#CD006404-sec2-0004}
-------------------------------------

In the absence of resistance, ACTs are effective drugs. However, with emerging resistance to the above currently recommended ACTs, it is necessary to identify new drug combinations with equivalent efficacy. This review is an update of a Cochrane Review first published in 2007 ([@CD006404-bbs2-0066]), and previously updated in 2014 ([@CD006404-bbs2-0065]). The latest update of this review concluded that pyronaridine‐artesunate performed well in these trials compared to artemether‐lumefantrine and mefloquine plus artesunate. At day 28, polymerase chain reaction (PCR)‐adjusted treatment failure (where PCR is used to confirm recrudescence rather than reinfection) was below the 5% standard set by the WHO. However, the review recommended further efficacy and safety studies in African and Asian children to clarify whether the combination is an option for first‐line treatment of uncomplicated *P falciparum* malaria.

Following this review, the latest edition of the WHO guidelines for the treatment of malaria did not recommend pyronaridine‐artesunate for general use ([@CD006404-bbs2-0062]). The Guideline Development Group recommended further data were required for efficacy in children less than five years of age, and safety, including safety of repeat dosing. They noted the undesirable effects of elevated liver function tests.

Since the previous update and WHO Guidelines, the West African Network for Clinical Trials of Antimalarial Drugs has published a new study of pyronaridine‐artesunate ([@CD006404-bbs2-0008]), and the European Medicines Agency (EMA) has adopted a positive scientific opinion of pyronaridine‐artesunate ([@CD006404-bbs2-0036]). In view of this, we have updated the review to inform future guideline development.

Objectives {#CD006404-sec1-0003}
==========

To evaluate the efficacy of pyronaridine‐artesunate compared to alternative ACTs for treating people with uncomplicated *P falciparum* malaria, and to evaluate the safety of pyronaridine‐artesunate and other pyronaridine treatments compared to alternative treatments.

Methods {#CD006404-sec1-0004}
=======

Criteria for considering studies for this review {#CD006404-sec2-0005}
------------------------------------------------

### Types of studies {#CD006404-sec3-0001}

Randomized controlled trials (RCTs).

### Types of participants {#CD006404-sec3-0002}

Adults and children with uncomplicated *Plasmodium falciparum* (*P falciparum*) malaria, as confirmed by either microscopy or rapid diagnostic tests.

For an additional safety analysis we extended the inclusion criteria to adults and children with *P vivax* malaria.

### Types of interventions {#CD006404-sec3-0003}

#### Intervention {#CD006404-sec4-0001}

Pyronaridine‐artesunate

#### Control {#CD006404-sec4-0002}

World Health Organization (WHO)‐recommended artemisinin‐based combination therapies (ACTs) for treating malaria

For the analysis of adverse events, we extended the inclusion criteria to all RCTs comparing pyronaridine alone or in combination with any other antimalarial.

### Types of outcome measures {#CD006404-sec3-0004}

#### Primary outcomes {#CD006404-sec4-0003}

Total treatment failure at day 28 (PCR‐adjusted and unadjusted)Total treatment failure at day 42 (PCR‐adjusted and unadjusted)

#### Secondary outcomes {#CD006404-sec4-0004}

Early treatment failure ([@CD006404-bbs2-0060]):danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitaemiaparasitaemia on day 2 higher than on day 0, irrespective of axillary temperatureparasitaemia on day 3 with axillary temperature ≥ 37.5 °Cparasitaemia on day 3 ≥ 25% of count on day 0

##### Adverse events (safety analysis) {#CD006404-sec5-0001}

Serious adverse events (leading to death, requiring hospitalization or prolongation of existing hospitalization, are life threatening, or result in persistent or significant disability or incapacity)Adverse events leading to withdrawal from treatment (discontinuation of trial drug or withdrawal from trial)Elevated liver function testsOther adverse events

##### Comment on outcome measures {#CD006404-sec5-0002}

We base our primary outcome measures on WHO recommendations ([@CD006404-bbs2-0058]; [@CD006404-bbs2-0060]), which advise a 28‐day follow‐up to capture most failures, and 42‐day follow‐up to capture failures for drugs with a longer elimination half‐life (mefloquine and piperaquine). This is also consistent with previous Cochrane Reviews. We do not report 'adequate clinical and parasitological response\' as this is defined in terms of absence of failure and therefore represents duplication.

The previous published protocol for this review listed a priori secondary outcomes to include parasite clearance, fever clearance, and gametocyte carriage ([@CD006404-bbs2-0065]). The protocol did not clearly define these outcomes, including whether they refer to durations, rates, or proportions of patients at given time points. We encountered considerable heterogeneity in these measures between studies, and therefore present a narrative synthesis.

We encountered heterogeneity in the threshold at which elevated liver function tests were deemed by study authors to be significant, which we have detailed in [Table 9](#CD006404-tbl-0009){ref-type="table"}. The reader should note that these thresholds do not necessarily correspond with internationally accepted definitions of drug‐induced liver injury ([@CD006404-bbs2-0028], summarized in [Appendix 1](#CD006404-sec2-0015){ref-type="app"}).Table 1Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin increase grading**TrialALT increased (grade 3 and above)AST increased (grade 3 and above)Blood bilirubin increased**[@CD006404-bbs2-0001]10 × ULN10 × ULN3 × ULN[@CD006404-bbs2-0003]\
[@CD006404-bbs2-0007]\
[@CD006404-bbs2-0008]\
[@CD006404-bbs2-0017]5 × ULN5 × ULN2.5 × ULN[@CD006404-bbs2-0006]\
[@CD006404-bbs2-0016]3 × ULN3 × ULN‐[@CD006404-bbs2-0002]3 × ULN if associated with bilirubin \> 2 × ULN‐‐[^6]

Search methods for identification of studies {#CD006404-sec2-0006}
--------------------------------------------

We sought to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD006404-sec3-0005}

The review authors and the Cochrane Infectious Diseases Group (CIDG) Information Specialist, Vittoria Lutje (VL), attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). The date of the last search was 8 May 2018.

VL searched the following databases using the search terms and strategy described in [Appendix 2](#CD006404-sec2-0016){ref-type="app"}: the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (PubMed, from 1966); Embase (OVID; from 1947); and LILACS (BIREME; from 1982). We also searched ClinicalTrials.gov ([clinicaltrials.gov](clinicaltrials.gov)), the WHO International Clinical Trial Registry Platform (ICTRP; [www.who.int/ictrp/search/en](www.who.int/ictrp/search/en)), and the International Standard Randomized Controlled Trial Number (ISRCTN) registry ([www.isrctn.com/](www.isrctn.com/)) for ongoing or recently completed trials using \'pyronaridine\', \'pyramax\', and \'malaria\' as search terms.

### Searching other resources {#CD006404-sec3-0006}

#### Conference proceedings {#CD006404-sec4-0005}

The previous authors of this review searched conference proceedings for relevant abstracts ([@CD006404-bbs2-0065]). We did not handsearch conference proceedings for this update as relevant abstracts are likely to be indexed and detected by the electronic search.

#### Reference lists {#CD006404-sec4-0006}

We checked the reference lists of all trials identified by the above methods.

#### Contacting organizations and experts {#CD006404-sec4-0007}

We did not formally contact experts for this update.

Data collection and analysis {#CD006404-sec2-0007}
----------------------------

### Selection of studies {#CD006404-sec3-0007}

For this review update, Joseph Pryce (JP) and Paul Hine (PH) independently screened the results of the search update to identify potentially relevant trials and obtain the full‐text reports of these trials. JP and PH used a standard eligibility form to assess newly identified studies. There were no disagreements. Due to the change in authorship, and to ensure validity, we rescreened all the results of the search, and verified the eligibility of previously included studies. We documented the reason for excluding trials in the '[Characteristics of excluded studies](#CD006404-sec2-0024){ref-type="sec"}\' table. We prepared a PRISMA diagram to summarise the identification, screening, and inclusion of studies in this review ([@CD006404-bbs2-0046]).

### Data extraction and management {#CD006404-sec3-0008}

For this update, to ensure accuracy and consistency, the new authors (JP and PH) independently re‐extracted all data using a new data extraction form.

#### Unadjusted total failure rate: day 28, day 42 {#CD006404-sec4-0008}

We extracted the following data, and summed it, to form the numerator.

Early treatment failure.Late clinical failure.Late parasitological failure.

We aimed to extract the following data, and subtract it from the number of participants randomized, to form the denominator.

Those found not to be fulfilling inclusion criteria after randomization.Those voluntarily withdrawing consent.Those lost to follow‐up.Those violating protocol, including (but not limited to) missed or vomited doses, those failing to complete treatment, and those taking additional antimalarials.

#### PCR‐adjusted total failure rate: day 28, day 42 {#CD006404-sec4-0009}

We aimed to extract the following data, and sum it, to form the numerator.

Early treatment failure due to PCR‐confirmed recrudescence.Late clinical failure due to PCR‐confirmed recrudescence.Late parasitological failure due to PCR‐confirmed recrudescence.

We aimed to extract the following data, and subtract it from the number of participants randomized, to form the denominator.

Those with indeterminate PCR results.Those with missing PCR results.Those with PCR‐confirmed new infections.Those found not to be fulfilling inclusion criteria after randomization.Those voluntarily withdrawing consent.Those lost to follow‐up.Those violating protocol, including (but not limited to) missed or vomited doses, those failing to complete treatment, and those taking additional antimalarials.

#### Adverse events data {#CD006404-sec4-0010}

For adverse events, we extracted the number of people experiencing the events in each study as the numerator. In contrast to the efficacy analysis, we extracted the number of people who received at least one dose of the study drug as the denominator. Recognising that studies often use different terminology to describe adverse events, we referenced the Medical Dictionary for Regulatory Activities to find the preferred term ([@CD006404-bbs2-0044]), and grouped adverse events according to MedDRA\'s \"High Level Term\" descriptors.

#### Comment on data extraction {#CD006404-sec4-0011}

This approach is based on standard WHO definitions ([@CD006404-bbs2-0058]; [@CD006404-bbs2-0060]). The WHO protocol has a primary goal to \"provide guidance in obtaining the minimum essential information about the clinical and parasitological response to antimalarial drugs among populations at greatest risk of severe morbidity or mortality due to malaria\" ([@CD006404-bbs2-0058]). Many antimalarial efficacy studies have used adapted versions of this protocol since its publication. Within this protocol, a high number of randomized participants are excluded from the final efficacy outcome as losses to follow‐up or voluntary or involuntary withdrawals.

In some instances, we could not extract the individual components required to form the denominator. We discuss this issue further in '[Dealing with missing data](#CD006404-sec3-0012){ref-type="sec"}\' below.

The primary outcomes relate to failure due to *P falciparum.* The denominators for each include participants developing *P vivax* parasitaemia that continued to be followed up within the trial.

### Assessment of risk of bias in included studies {#CD006404-sec3-0009}

For this review update, JP and PH assessed the risk of bias for the new trial inclusion using the Cochrane tool for assessing risk of bias ([@CD006404-bbs2-0039]). JP and PH assigned a judgement of 'high risk\', 'low risk\', and 'unclear risk\' to each domain recording these in 'Risk of bias\' tables, and a summary 'Risk of bias\' graph.

For efficacy, we assessed the following domains.

Sequence generation.Allocation concealment.Blinding of participants, trial personnel and outcome assessors.Incomplete outcome data.Selective reporting.Other sources of bias.

For adverse events, we assessed the two following domains, selected based on Cochrane and PRISMA recommendations ([@CD006404-bbs2-0042]; [@CD006404-bbs2-0064]).

Adverse event detection.Incomplete reporting of adverse events.

[Appendix 3](#CD006404-sec2-0017){ref-type="app"} gives examples of 'Risk of bias\' assessment decisions.

### Measures of treatment effect {#CD006404-sec3-0010}

We extracted data from each included trial to calculate risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous data. We present all measures with the corresponding 95% confidence interval (CI).

### Unit of analysis issues {#CD006404-sec3-0011}

We did not encounter any unit of analysis issues.

### Dealing with missing data {#CD006404-sec3-0012}

In the event of missing or unclear data, we contacted trial authors for clarifications or to provide further information. It was not always possible to extract each data item required to itemise the denominator for treatment failures, particularly where study authors reported amalgamations of the denominator component. Where this was the case, we kept clear records of inferences made to inform the denominator data.

### Assessment of heterogeneity {#CD006404-sec3-0013}

We visually inspected the forest plots for overlapping CIs as an indicator of clinical heterogeneity. We also took into account Chi^2^ and I^2^ tests of heterogeneity. We considered a Chi^2^ test P \< 0.1 and/or an I^2^ statistic \> 75% as indicating substantial heterogeneity. If we judged there to be substantial heterogeneity we did not pool the results in a meta‐analysis, and instead presented a narrative synthesis of the findings.

### Assessment of reporting biases {#CD006404-sec3-0014}

There were too few trials to examine funnel plot asymmetry for evidence of small trial effects or publication bias.

### Data synthesis {#CD006404-sec3-0015}

We analysed data using [@CD006404-bbs2-0053]. For the primary analysis we stratified by comparator ACT. We performed meta‐analysis where appropriate after assessment and investigation of heterogeneity. In the first instance, we used a fixed‐effect model. Where there was evidence of heterogeneity, we used a random‐effects model, and applied this consistently across similar outcomes.

We deemed it inappropriate to combine continuous data for the outcomes of parasite clearance, fever clearance and gametocyte carriage, due to heterogeneity in the measurements of these outcomes.

### Subgroup analysis and investigation of heterogeneity {#CD006404-sec3-0016}

We intended to explore causes of heterogeneity using subgroup analysis of age, country and geographic region. We deemed that there were too few trials to use these subgroup analyses. However, to explore the applicability of the evidence to child populations, we presented the findings from a subset of trials that exclusively recruited paediatric participants.

### Sensitivity analysis {#CD006404-sec3-0017}

We planned to conduct a series of sensitivity analyses as detailed in [Appendix 4](#CD006404-sec2-0018){ref-type="app"}. The aim of this was to restore the integrity of the randomizations process by adding excluded groups back into the analysis in a stepwise fashion. However, as we were unable to reliably extract data pertinent to the missing or indeterminate PCR values, we did not conduct the sensitivity analysis.

#### Certainty of the evidence {#CD006404-sec4-0012}

We assessed the certainty of the evidence using the GRADE approach ([@CD006404-bbs2-0055]). We appraised the certainty of the evidence in relation to the following criteria.

Study designRisk of biasInconsistencyIndirectnessImprecisionOther considerations (including publication bias)

We used [@CD006404-bbs2-0038] to create 'Summary of findings\' tables for each comparison included in the review. We included our primary outcomes and adverse event outcomes, and used the tables to guide our conclusions.

Results {#CD006404-sec1-0005}
=======

Description of studies {#CD006404-sec2-0008}
----------------------

See [Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"} and [Characteristics of excluded studies](#CD006404-sec2-0024){ref-type="sec"} sections.

### Results of the search {#CD006404-sec3-0018}

The search (dated 8 May 2018) identified 40 database records and 12 trials registry records. After contacting authors of a relevant registered trial, we obtained one additional published record. JP and PH independently screened all titles. This process replaced that of the previous version of this review ([@CD006404-bbs2-0065]), as we are a new authorship team.

We identified 31 potentially relevant full‐text records through title and abstract screening. We excluded 10 records after further assessment (see '[Characteristics of excluded studies](#CD006404-sec2-0024){ref-type="sec"}\' table).

This process identified 21 records, relating to 10 studies, which we included in qualitative and quantitative synthesis (see [Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"}). We identified four studies that were not included in the previous version of this review ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]).

The [@CD006404-bbs2-0008] trial compared different drug combinations at different sites, but presented the results in an aggregated analysis, in which the numbers of outcome events were summarized across sites. We were concerned that this presented an unpredictable bias and so contacted the trial authors to obtain data disaggregated to site level for the efficacy and raised liver enzyme outcomes. We were therefore able to present the data from individual sites separately in the meta‐analysis. However, we did not have disaggregated data for the outcomes of serious adverse events or adverse events leading to withdrawal of treatment. We therefore present these outcomes in narrative form. Further details of the comparisons examined and the number of participants are provided in the '[Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"}\' tables for each site.

[Figure 1](#CD006404-fig-0001){ref-type="fig"} illustrates the search results in a flow diagram (PRISMA).Figure 1Study flow diagram.

### Included studies {#CD006404-sec3-0019}

#### Studies meeting the inclusion criteria for efficacy outcomes {#CD006404-sec4-0013}

Five studies met the inclusion criteria for efficacy outcomes ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]; see [Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"}). Each of the studies had a length of follow‐up of 42 days.

##### Comparison 1: Pyronaridine‐artesunate versus artemether‐lumefantrine {#CD006404-sec5-0003}

Four randomized controlled trials (RCTs) evaluated this comparison ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]).

Sample sizes ranged from 197 participants in [@CD006404-bbs2-0006] to 1323 participants in [@CD006404-bbs2-0008], yielding a total number of 3327 for inclusion in quantitative synthesis. Two studies were multicentred in Africa and Asia ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0017]), one was multicentred in Africa ([@CD006404-bbs2-0008]), and one was a single‐centre in Africa ([@CD006404-bbs2-0006]). None of the studies described the *P falciparum* resistance profile to currently available antimalarials. In total, 3128 (94%) participants were recruited in Africa, and 213 (6%) participants were recruited in Asia.

Two studies included adults and children ([@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]), and two studies included children only ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0006]). In total, 541 (16%) participants were aged less than five years. All studies included both male and female participants. In total 1568 (47%) participants were female.

All studies used three‐day regimens of pyronaridine‐artesunate with dose adjusted according to weight. There were minimal differences in dose by weight. The two paediatric trials used granule formulation.

All studies reported \"adequate clinical and parasitological response\" rate) at day 28 and day 42, PCR‐adjusted and unadjusted. All studies also reported parasite clearance time (defined as first dose to aparasitaemia), and fever clearance time (defined as first dose to apyrexia).

##### Comparison 2: Pyronaridine‐artesunate versus artesunate‐amodiaquine {#CD006404-sec5-0004}

One RCT evaluated this comparison, taking place in multiple centres in West Africa ([@CD006404-bbs2-0008]). The study did not describe the *P falciparum* resistance profile to currently available antimalarials. In total, 1317 participants randomized to this comparison received at least one study treatment. Of these, 477 (36%) participants were aged less than five years, and 658 (50%) participants were female.

Both pyronaridine‐artesunate and artesunate‐amodiaquine were administered once‐daily for three days at doses according to bodyweight.

##### Comparison 3: Pyronaridine‐artesunate versus mefloquine plus artesunate {#CD006404-sec5-0005}

A single trial evaluated this comparison ([@CD006404-bbs2-0007]).

The sample size was 1271 participants. Most participants (1033, 81.3%) were from Asia (Cambodia, India, Thailand, and Vietnam), with a smaller number (238, 18.7%) from Africa (Burkina Faso, Ivory Coast, and Tanzania). Malaria endemicity was described by the trial authors as high in most sites. In Cambodia, significantly extended parasite clearance times (for both treatment arms) were suggestive of in vivo resistance to artemisinin. The resistance in the other sites or to other antimalarials was not described. The trial planned to recruit participants aged between three to 60 years, the youngest participant was five years old.

Both pyronaridine‐artesunate and mefloquine plus artesunate were administered once‐daily for three days. The trial did not use a fixed dose combination of mefloquine and artesunate. The mefloquine dose ranged from 6.2 mg/kg to 12.5 mg/kg and the artemether dose ranged from 2.2 mg/kg to 5.0 mg/kg.

#### Studies meeting the inclusion criteria for safety outcomes {#CD006404-sec4-0014}

In addition to the five studies meeting the inclusion criteria for efficacy, we included five further studies which met the inclusion criteria for safety outcomes. Two studies had a follow‐up period of 14 days ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]), two had a follow‐up of 42 days ([@CD006404-bbs2-0003]; [@CD006404-bbs2-0016]), and one study followed up for one year ([@CD006404-bbs2-0002]).

Of these, we included three in a meta‐analysis pertaining to serious adverse events and liver function tests ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0016]), in addition to the studies included in the efficacy analysis. These three studies contributed a further 666 participants to the meta‐analysis, and included participants with *P vivax* malaria recruited from sites in Asia. One study included only adult male soldiers ([@CD006404-bbs2-0002]). No participants were aged less than five years. Two studies excluded participants with existing hepatic impairment ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]). Further details of the inclusion and exclusion criteria are provided in the '[Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"}\' tables.

The [@CD006404-bbs2-0002] study compared pyronaridine‐artesunate versus artesunate alone or dihydroartemisinin‐piperaquine. The other two studies were based on the same protocol ([@CD006404-bbs2-0003]; [@CD006404-bbs2-0016]), and compared pyronaridine‐artesunate versus chloroquine.

We included two further studies ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]), contributing a further 184 participants, in the analysis of other adverse events; these studies compared pyronaridine monotherapy to chloroquine.

As is common to clinical trials, patients with known or suspected pre‐existing liver dysfunction were excluded. Concomitant paracetamol (acetaminophen) administration was allowed in at least two of the trial protocols ([@CD006404-bbs2-0003], [@CD006404-bbs2-0008]), but the remaining trials do not record whether concomitant paracetamol was allowed or to the extent that it was used.

### Excluded studies {#CD006404-sec3-0020}

We excluded 10 records after further assessment (see [Characteristics of excluded studies](#CD006404-sec2-0024){ref-type="sec"}).

Two were quasi‐RCTs, three were RCTs that were not relevant to this review, and five were not RCTs.

Risk of bias in included studies {#CD006404-sec2-0009}
--------------------------------

See [Figure 2](#CD006404-fig-0002){ref-type="fig"}.Figure 2'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD006404-sec3-0021}

Seven studies reported the use of computer generated allocation sequences ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]). The [@CD006404-bbs2-0002] study reported \"statistician block‐allocated treatment\". Two studies reported block randomization, but it is unclear how blocks were generated ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]). We judged random sequence generation to present a low risk of bias across studies.

Five studies concealed allocation using sealed opaque envelopes ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]). Three studies concealed allocation using individually numbered treatment packs ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0017]). Two studies reported central randomization in correspondence with the previous authors of this review ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]). We judged allocation concealment to present a low risk of bias across studies.

### Blinding {#CD006404-sec3-0022}

Five studies reported that the participants were blinded to treatment allocation ([@CD006404-bbs2-0003]; [@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0017]). Six studies reported that the investigators performing clinical assessments were blinded to treatment allocation ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]). Eight studies reported that the investigators performing parasitological assessments were blinded to treatment allocation ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]).

Notwithstanding the different degrees to which studies were blinded, we judged there to be a low risk of performance bias and detection bias in relation to the outcomes assessed.

### Incomplete outcome data {#CD006404-sec3-0023}

All of the included trials reported attrition with details of all randomized participants. Our analysis focused on evaluable participants. We did not have concerns that there was differential loss to follow‐up between interventions.

### Selective reporting {#CD006404-sec3-0024}

We located trial registration documents for eight studies ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]). These appeared to be free of selective reporting based on comparison of registration documents and trial protocols, where available. Though trial registration documents were not available for the remaining two studies ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]), we also considered them to be at low risk of reporting bias, as all the expected outcomes were reported.

### Other potential sources of bias {#CD006404-sec3-0025}

Seven of the 10 included studies were funded by the public‐private partnership of Medicines for Malaria Venture and Shin Poong Pharmaceuticals ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]). The Medicines for Malaria Venture and/or Shin Poong Pharmaceuticals employed study authors in six of these studies ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]). We considered this to pose low risk of bias as all authors took responsibility for reporting accuracy, apart from in one study ([@CD006404-bbs2-0016]), where the lead authors were Shin Poong Pharmaceuticals employees.

Of the remaining three studies not funded by Medicines for Malaria Venture and Shin Poong Pharmaceuticals, one assessed pyronaridine‐artesunate ([@CD006404-bbs2-0006]); the other two assessed pyronaridine monotherapy ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]), and did not contribute to the main analyses.

We considered one study to have unclear risk of other bias in relation to bioavailability of lumefantrine ([@CD006404-bbs2-0017]).

#### Adverse event monitoring (detection bias) {#CD006404-sec4-0015}

Seven studies provided unclear descriptions, definitions, or schedules for adverse advent monitoring, and therefore we deemed them to have unclear risk of detection bias for adverse events ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]). We deemed the remaining studies to be at low risk of detection bias for adverse events ([@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]).

#### Incomplete adverse event reporting (reporting bias) {#CD006404-sec4-0016}

In five studies we identified unclear reporting of adverse events, with differences in reporting numbers or thresholds, and deemed these to have unclear risk of reporting bias for adverse events ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]). We judged the remaining studies to be at low risk of reporting bias for adverse events ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]).

Effects of interventions {#CD006404-sec2-0010}
------------------------

See: [Table 1](#CD006404-tbl-0001){ref-type="table"}; [Table 2](#CD006404-tbl-0002){ref-type="table"}; [Table 3](#CD006404-tbl-0003){ref-type="table"}; [Table 4](#CD006404-tbl-0004){ref-type="table"}

### Comparison 1. Pyronaridine‐artesunate versus artemether‐lumefantrine {#CD006404-sec3-0026}

Four studies with 3341 participants contributed data to this comparison ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]).

#### Total treatment failure (PCR‐adjusted) {#CD006404-sec4-0017}

In the pooled analysis, there were fewer PCR‐adjusted treatment failures at day 28 following treatment with pyronaridine‐artesunate compared to artemether‐lumefantrine, but the CI crossed the line of no effect (risk ratio (RR) 0.59, 95% CI 0.26 to 1.31; 4 trials, 3068 participants; [Analysis 1.2](#CD006404-fig-00102){ref-type="fig"}). There was little or no difference at day 42 (RR 0.86, 95% CI 0.49 to 1.51; 4 trials, 2575 participants; [Analysis 1.1](#CD006404-fig-00101){ref-type="fig"}).

The PCR‐adjusted treatment failure rate for pyronaridine‐artesunate was less than 5% in all trials at day 28. At day 42, the PCR‐adjusted treatment failure rate for pyronaridine‐artesunate was slightly greater than 5% in two studies ([@CD006404-bbs2-0001], 18 events for 275 evaluable patients, 6.5%; [@CD006404-bbs2-0006], 4 events for 77 evaluable patients, 5.2%).

#### Total treatment failure (PCR‐unadjusted) {#CD006404-sec4-0018}

In the pooled analysis, there were fewer PCR‐unadjusted treatment failures following treatment with pyronaridine‐artesunate compared to artemether‐lumefantrine at day 28 (RR 0.27, 95% CI 0.13 to 0.58; 4 trials, 3149 participants; [Analysis 1.3](#CD006404-fig-00103){ref-type="fig"}) and at day 42 (RR 0.61, 95% CI 0.46 to 0.82, 4 trials, 3080 participants; [Analysis 1.4](#CD006404-fig-00104){ref-type="fig"}).

#### Early treatment failure {#CD006404-sec4-0019}

There were two events of early treatment failure which occurred in one trial ([@CD006404-bbs2-0001]), both in the pyronaridine‐artesunate arm (RR 2.53, 95% CI 0.12 to 52.39; 4 trials, 3149 participants; [Analysis 1.5](#CD006404-fig-00105){ref-type="fig"}).

#### Serious adverse events {#CD006404-sec4-0020}

We were unable to include the data on serious adverse events from one multicentre trial in the meta‐analysis because the data were not disaggregated by trial site ([@CD006404-bbs2-0008]), and participant randomization did not take place independently from site. Instead, we have summarized the number and nature of the serious adverse events in the trial in [Table 10](#CD006404-tbl-0010){ref-type="table"}. Across the other trials included in the quantitative synthesis, there were six serious adverse events, with four occurring in patients in the pyronaridine‐artesunate arm and two in patients in the artemether‐lumefantrine arm. There was no significant difference between treatments (RR 0.90, 95% CI 0.19 to 4.22; 3 trials, 2004 participants; [Analysis 1.6](#CD006404-fig-00106){ref-type="fig"}).Table 2Serious adverse events**StudyPyronaridine‐artesunateComparator(s)**[@CD006404-bbs2-0001]Severe malaria (1)^a^**Artemether‐lumefantrine**\
‐[@CD006404-bbs2-0002]Head trauma (1)^a^\
Typhoid fever (1)^b^\
Nephrolithiasis (1)^b^**Artesunate only**\
Metacarpal fracture (1)^a^\
Acute gastroenteritis (1)^a^\
Suspected ureteric stone (1)^b^\
**Dihydroartemisinin‐piperaquine**\
Dengue fever (1)^a^[@CD006404-bbs2-0003]Pyrexia (1)^a^\
Typhoid fever (1)^a^**Chloroquine**\
‐[@CD006404-bbs2-0004]‐‐[@CD006404-bbs2-0005]‐‐[@CD006404-bbs2-0006]‐‐[@CD006404-bbs2-0007]Autoimmune haemolytic anaemia (1)^a^ Cholera (1)^a^ Pneumonia (1)^a^ Acute pyelonephritis (1)^a^ Wound infection (1)^a^ Abortion (1)^a^ Depression (1)^a^**Mefloquine plus artesunate**\
Cerebral malaria (1)^a^ Seizure (1)^c^ Grand mal seizure (1)^c^[@CD006404-bbs2-0017]Parotitis (1)^a^\
Typhoid fever (1)^a^\
Urinary tract infection (1)^a^**Artemether‐lumefantrine**\
Cerebral malaria (1)^a^\
Immunosuppression (1)^a^[@CD006404-bbs2-0008]^d^Elevated ALT (2)^c^\
Elevated AST (2)^c^\
Transaminases increased (4)^c^\
Drug‐induced liver injury (1)^c^\
Hypercreatininemia (1)^c^**Artemether‐lumefantrine**\
Drug‐induced liver injury (1)^c^\
Toxic epidermal necrolysis (1)^c^\
**Artesunate‐amodiaquine**\
Drug‐induced liver injury (1)^c^\
Transaminases increased (2)^c^[^7]

#### Adverse events leading to withdrawal from treatment {#CD006404-sec4-0021}

We were unable to include data from one trial ([@CD006404-bbs2-0008]), for the same reason as given above. Across the other trials included in quantitative synthesis, there were 37 events leading to withdrawal from treatment, with 27 occurring in patients in the pyronaridine‐artesunate arm and 10 in patients in the artemether‐lumefantrine arm. There was no significant difference between treatments (RR 1.41, 95% CI 0.68 to 2.90; 3 trials, 2004 participants; [Analysis 1.7](#CD006404-fig-00107){ref-type="fig"}).

#### Elevated liver function tests {#CD006404-sec4-0022}

Following first treatment, the proportion of participants with raised alanine aminotransferase (ALT) greater than five times the upper limit of normal (\> 5 x ULN) was higher in those treated with pyronaridine‐artesunate compared to artemether‐lumefantrine (RR 2.92, 95% CI 1.15 to 7.41; 4 trials, 3327 participants; [Analysis 1.8](#CD006404-fig-00108){ref-type="fig"}, [Figure 3](#CD006404-fig-0003){ref-type="fig"}). There were 0 events in either arm of one study ([@CD006404-bbs2-0006]), so this did not contribute to the relative risk calculation.Figure 3Forest plot of comparison 1: Pyronaridine‐artesunate versus artemether‐lumefantrine, outcome 1.8: ALT increase \> 5 × ULN, first treatment.

There was no significant difference in raised aspartate transaminase (AST) \> 5 x ULN (RR 2.20, 95% CI 0.83 to 5.82; 4 trials, 3327 participants; [Analysis 1.9](#CD006404-fig-00109){ref-type="fig"}) or bilirubin \> 2.5 x ULN (RR 0.82, 95% CI 0.33 to 2.04; 3 trials, 3130 participants; [Analysis 1.10](#CD006404-fig-00110){ref-type="fig"}) between pyronaridine‐artesunate and artemether‐lumefantrine.

One trial investigated the rate of elevated liver function tests in patients receiving second or subsequent treatments with pyronaridine‐artesunate compared to artemether‐lumefantrine ([@CD006404-bbs2-0008]). The rates of such events were low in each treatment arm. In a pooled analysis across the trial sites we detected no significant differences in the number of raised ALT (\> 5 x ULN), AST (\> 5 x ULN), or bilirubin (\> 2.5 x ULN) events between pyronaridine‐artesunate and artemether‐lumefantrine (1 trial, 865 participants; [Analysis 1.11](#CD006404-fig-00111){ref-type="fig"}; [Analysis 1.12](#CD006404-fig-00112){ref-type="fig"}; [Analysis 1.13](#CD006404-fig-00113){ref-type="fig"}).

#### Subgroup analysis {#CD006404-sec4-0023}

When we included only the two trials which studied paediatric populations exclusively ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0006]), we did not find differences in efficacy or safety outcomes between pyronaridine‐artesunate and artemether‐lumefantrine (2 trials, 732 participants in safety analysis; [Analysis 1.14](#CD006404-fig-00114){ref-type="fig"}; [Analysis 1.15](#CD006404-fig-00115){ref-type="fig"}; [Analysis 1.16](#CD006404-fig-00116){ref-type="fig"}; [Analysis 1.17](#CD006404-fig-00117){ref-type="fig"}; [Analysis 1.18](#CD006404-fig-00118){ref-type="fig"}; [Analysis 1.19](#CD006404-fig-00119){ref-type="fig"}). We were unable to extract disaggregated data for children from the other two trials ([@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]).

There were not enough studies to perform further subgroup analyses or investigation of heterogeneity.

#### Narrative synthesis of other reported outcomes {#CD006404-sec4-0024}

Three studies also reported fever and parasite clearance times, which were broadly comparable between pyronaridine‐artesunate and artemether‐lumefantrine ([Table 11](#CD006404-tbl-0011){ref-type="table"}). Differences in reporting precluded quantitative synthesis.Table 3Pyronaridine‐artesunate (PY‐AS) versus artemether‐lumefantrine (AL): other reported outcomes**TrialFever clearance timeParasite clearance timePY‐ASALPY‐ASAL**[@CD006404-bbs2-0001]Median 8.1 h (95% CI 8.0 to 8.1)Median 8.1 h (95% CI 8.0 to 15.8)Median 24.1 h (95% CI 24.0 to 24.1)Median 24.2 h (95% CI 24.1 to 32.0)[@CD006404-bbs2-0006]Median 1 day (1‐1)Median 1 day (1‐1)Median 1 day (1‐2)Median 2 days (1‐2)[@CD006404-bbs2-0017]Mean 13.6 h (SD 8.9)Mean 14.8 h (SD 10.1)23.3 h (SD 8.8)26.5 h (10.1)[^8]

### Comparison 2. Pyronaridine‐artesunate versus artesunate‐amodiaquine {#CD006404-sec3-0027}

One study with 1336 participants contributed data to this comparison ([@CD006404-bbs2-0008]). We extracted data disaggregated by site as described in [Results of the search](#CD006404-sec3-0018){ref-type="sec"}, and presented them separately in our meta‐analyses.

#### Total treatment failure (PCR‐adjusted) {#CD006404-sec4-0025}

In the pooled analysis across the multiple sites, there were fewer PCR‐adjusted treatment failures at day 28 for pyronaridine‐artesunate compared to artesunate‐amodiaquine, but the CI crossed the line of no effect (RR 0.55, 95% CI 0.11 to 2.77; 1 trial, 1245 participants; [Analysis 2.1](#CD006404-fig-00201){ref-type="fig"}). There was little or no difference in PCR‐adjusted treatment failure at day 42 (RR 0.98, 95% CI 0.20 to 4.83; 1 trial, 1091 participants; [Analysis 2.2](#CD006404-fig-00202){ref-type="fig"}).

The PCR‐adjusted treatment failure rate for pyronaridine‐artesunate was less than 5% in all sites at both day 28 and day 42.

#### Total treatment failure (PCR‐unadjusted) {#CD006404-sec4-0026}

In pooled analysis, pyronaridine‐artesunate had fewer PCR‐unadjusted treatment failures compared to artesunate‐amodiaquine at day 28 (RR 0.49, 95% CI 0.30 to 0.81; 1 trial, 1257 participants; [Analysis 2.3](#CD006404-fig-00203){ref-type="fig"}). At day 42, there was little or no difference (RR 0.98, 95% CI 0.78 to 1.23; 1 trial, 1235 participants; [Analysis 2.4](#CD006404-fig-00204){ref-type="fig"}).

#### Early treatment failure {#CD006404-sec4-0027}

There was no early treatment failure reported in either the pyronaridine‐artesunate arm or the artesunate‐amodiaquine arm across all study sites (1336 participants, 1 trial).

#### Serious adverse events, adverse events leading to withdrawal from treatment {#CD006404-sec4-0028}

We were unable to include the trial\'s data on serious adverse events and adverse events leading to withdrawal in a meta‐analysis, for the reason given above. We summarized the number and nature of the serious adverse events in the trial in [Table 10](#CD006404-tbl-0010){ref-type="table"}.

#### Elevated liver function tests {#CD006404-sec4-0029}

Following first treatment, there was no significant difference in raised ALT \> 5 x ULN (RR 1.41, 95% CI 0.28 to 7.09; 1 trial, 1317 participants; [Analysis 2.5](#CD006404-fig-00205){ref-type="fig"}), raised AST \> 5 x ULN (RR 0.40, 95% CI 0.08 to 2.07; 1 trial, 1317 participants, [Analysis 2.6](#CD006404-fig-00206){ref-type="fig"}), or raised bilirubin \> 2.5 x ULN (RR 0.99, 95% CI 0.06 to 15.76; 1 trial, 1317 participants; [Analysis 2.7](#CD006404-fig-00207){ref-type="fig"}) between pyronaridine‐artesunate and artesunate‐amodiaquine.

Similarly, on second or subsequent treatments, we detected no significant difference in the number of raised ALT (\> 5 x ULN), AST (\> 5 x ULN) or bilirubin (\> 2.5 x ULN) events between pyronaridine‐artesunate and artesunate‐amodiaquine treatment arms (784 participants, 1 trial ([Analysis 2.8](#CD006404-fig-00208){ref-type="fig"}; [Analysis 2.9](#CD006404-fig-00209){ref-type="fig"}; [Analysis 2.10](#CD006404-fig-00210){ref-type="fig"}).

### Comparison 3. Pyronaridine‐artesunate versus mefloquine plus artesunate {#CD006404-sec3-0028}

One study with 1271 participants contributed data to this comparison ([@CD006404-bbs2-0007]).

#### Total treatment failure (PCR‐adjusted) {#CD006404-sec4-0030}

There were fewer PCR‐adjusted treatment failures at day 28 for pyronaridine‐artesunate compared to mefloquine plus artesunate, but the CI crossed the line of no effect (RR 0.37, 95% CI 0.13 to 1.05; 1 trial, 1117 participants; [Analysis 3.1](#CD006404-fig-00301){ref-type="fig"}). There were more PCR‐adjusted treatment failures at day 42 for pyronaridine‐artesunate compared to mefloquine plus artesunate, but the CI crossed the line of no effect (RR 1.80, 95% CI 0.90 to 3.57; 1 trial, 1037 participants; [Analysis 3.2](#CD006404-fig-00302){ref-type="fig"}).

The PCR‐adjusted treatment failure rate for pyronaridine‐artesunate was less than 5% at day 28. At day 42, the PCR‐adjusted treatment failure rate for pyronaridine‐artesunate was slightly greater than 5% (37 events for 698 evaluable patients, 6.5%).

#### Total treatment failure (PCR‐unadjusted) {#CD006404-sec4-0031}

Pyronaridine‐artesunate had fewer PCR‐unadjusted treatment failures compared to mefloquine plus artesunate at day 28 (RR 0.36, 95% CI 0.17 to 0.78; 1 trial, 1120 participants; [Analysis 3.3](#CD006404-fig-00303){ref-type="fig"}). At day 42, there was little or no difference between pyronaridine‐artesunate and mefloquine plus artesunate (RR 0.84, 95% CI 0.54 to 1.31; 1 trial, 1059 participants; [Analysis 3.4](#CD006404-fig-00304){ref-type="fig"}).

#### Early treatment failure {#CD006404-sec4-0032}

There was one early treatment failure in the mefloquine plus artesunate arm of the study, and none in the pyronaridine‐artesunate arm.

#### Serious adverse events, adverse events leading to withdrawal from treatment {#CD006404-sec4-0033}

There was little or no difference in serious adverse events between pyronaridine‐artesunate and mefloquine plus artesunate (RR 1.00, 95% CI 0.25 to 3.97; 1 trial, 1271 participants; [Analysis 3.5](#CD006404-fig-00305){ref-type="fig"}). There was no significant different in adverse events leading to withdrawal from treatment (1271 participants, 1 trial; [Analysis 3.6](#CD006404-fig-00306){ref-type="fig"}).

#### Elevated liver function tests {#CD006404-sec4-0034}

There were higher rates of raised ALT \> 5 x ULN in the pyronaridine‐artesunate arm compared to the mefloquine plus artesunate arm, but the CIs crossed the line of no effect (RR 7.48, 95% CI 0.99 to 56.45; 1 trial, 1271 participants; [Analysis 3.7](#CD006404-fig-00307){ref-type="fig"}). We did not find a significant difference for the rate of raised AST \> 5 x ULN (RR 9.49, 95% CI 0.55 to 162.64; 1 trial, 1271 participants; [Analysis 3.8](#CD006404-fig-00308){ref-type="fig"}) or bilirubin \> 2.5 x ULN (RR 3.49, 95% CI 0.43 to 28.29; 1 trial, 1271 participants; [Analysis 3.9](#CD006404-fig-00309){ref-type="fig"}).

#### Narrative synthesis of other reported outcomes {#CD006404-sec4-0035}

The [@CD006404-bbs2-0007] study also reported fever, parasite and gametocyte clearance times, which were broadly comparable between pyronaridine‐artesunate and mefloquine plus artesunate ([Table 12](#CD006404-tbl-0012){ref-type="table"}).Table 4Pyronaridine‐artesunate (PY‐AS) versus mefloquine plus artesunate (MQ+AS): other reported outcomes**TrialFever clearance timeParasite clearance timeGametocyte clearance timePY‐ASMQ+ASPY‐ASMQ+ASPY‐ASMQ+AS**[@CD006404-bbs2-0007]Mean 19.3 h (SD 12.9)Mean 19.2 h (SD 12.5)Mean 35.9 h (SD 19.8)Mean 38.5 h (SD 20.1)Mean 25.5 h (SD 23.3)Mean 30.9 h (SD 19.9)[^9]

### Comparison 4. Pyronaridine‐artesunate versus any other antimalarial {#CD006404-sec3-0029}

Eight RCTs with 6614 participants contributed data to a safety meta‐analysis in which we compared pyronaridine‐artesunate to any other antimalarial. The comparators were artesunate alone, artemether‐lumefantrine, dihydroartemisin‐piperaquine, chloroquine, mefloquine plus artesunate, and artesunate‐amodiaquine. For the [@CD006404-bbs2-0008] trial, we extracted data disaggregated by site, as described in [Results of the search](#CD006404-sec3-0018){ref-type="sec"}, and we present them separately in meta‐analysis.

An additional two RCTs compared pyronaridine monotherapy to chloroquine ([@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]), and contributed to the quantitative and qualitative synthesis of other adverse events (excluding serious adverse events or liver enzymes).

All trials contributing to the safety meta‐analysis excluded participants with baseline hepatic impairment.

#### Serious adverse events {#CD006404-sec4-0036}

We detected little or no difference in the rate of serious adverse events with pyronaridine‐artesunate compared to other antimalarials (RR 1.24, 95% CI 0.54 to 2.84; 7 trials, 3941 participants; [Analysis 4.1](#CD006404-fig-00401){ref-type="fig"}). We were unable to include data from the [@CD006404-bbs2-0008] trial in this meta‐analysis, as explained above.

To provide a narrative synthesis, we summarized the nature and number of serious adverse events in [Table 10](#CD006404-tbl-0010){ref-type="table"}. In the pyronaridine‐artesunate arm, we judged 10 of 26 serious adverse events across 10 trials to be related to treatment with pyronaridine‐artesunate or pyronaridine alone ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0002]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0016]; [@CD006404-bbs2-0017]), with each of these coming in the [@CD006404-bbs2-0008] trial. In comparison, we judged two of four events in the artemether‐lumefantrine arm ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]), three of three in the artesunate‐amodiaquine arm ([@CD006404-bbs2-0008]), and two of three in the mefloquine plus artesunate arm ([@CD006404-bbs2-0007]), to be related to the treatment. We did not judge the sole serious adverse event seen with dihydroartemisinin‐piperaquine and the three seen in the artesunate only arm to be related to treatment ([@CD006404-bbs2-0002]). No serious adverse events were seen in the chloroquine arm ([@CD006404-bbs2-0003]; [@CD006404-bbs2-0004]; [@CD006404-bbs2-0005]; [@CD006404-bbs2-0006]).

#### Adverse events leading to withdrawal from treatment {#CD006404-sec4-0037}

We detected little or no differences in the rate of adverse events leading to withdrawal from treatment with pyronaridine‐artesunate compared to other antimalarials (RR 1.06, 95% CI 0.58 to 1.94; 6 trials, 3911 participants; [Analysis 4.2](#CD006404-fig-00402){ref-type="fig"}).

#### Elevated liver function tests {#CD006404-sec4-0038}

##### Quantitative synthesis {#CD006404-sec5-0006}

Different studies defined rises in ALT, AST, and bilirubin as important at different levels, ranging from 3 x ULN to 10 x ULN. The differences between definitions of important rises are shown in [Table 9](#CD006404-tbl-0009){ref-type="table"}.

Following first treatment, pyronaridine‐artesunate was associated with a greater incidence of raised ALT \> 5 x ULN compared to other antimalarials (RR 3.34, 95% CI 1.63 to 6.84; 8 trials, 6581 participants; [Analysis 4.3](#CD006404-fig-00403){ref-type="fig"}, [Figure 4](#CD006404-fig-0004){ref-type="fig"}). Pyronaridine‐artesunate was also associated with a greater incidence of raised AST \> 5 x ULN compared to other antimalarials, but the CIs crossed the line of no effect (RR 1.80, 95% CI 0.89 to 3.65; 8 trials, 6581 participants; [Analysis 4.4](#CD006404-fig-00404){ref-type="fig"}). We detected little or no difference in raised bilirubin \> 2.5 x ULN events (RR 1.03, 95% CI 0.49 to 2.18; 7 trials, 6384 participants; [Analysis 4.5](#CD006404-fig-00405){ref-type="fig"}).Figure 4Forest plot of comparison 4: Pyronaridine‐artesunate versus other antimalarials, outcome: 4.3 ALT increase \> 5 × ULN, first treatment.

For second or subsequent treatments, we detected no significant differences in the number of raised ALT (\> 5 x ULN), AST (\> 5 x ULN) or bilirubin (\> 2.5 x ULN) events between pyronaridine‐artesunate and other antimalarials (1649 participants, 1 trial; [Analysis 4.6](#CD006404-fig-00406){ref-type="fig"}; [Analysis 4.7](#CD006404-fig-00407){ref-type="fig"}; [Analysis 4.8](#CD006404-fig-00408){ref-type="fig"}). There were small numbers in each arm.

A sensitivity analysis confined to only those trials which used the same grading for severely raised ALT also found that those treated with pyronaridine‐artesunate had a greater incidence of raised ALT \> 5 x ULN compared to other antimalarials (RR 4.07, 95% CI 1.83 to 9.05; 4 trials, 5672 participants; [Analysis 4.9](#CD006404-fig-00409){ref-type="fig"}).

##### Qualitative (narrative) synthesis {#CD006404-sec5-0007}

[@CD006404-bbs2-0004] reported that five out of 40 participants given pyronaridine had elevated bilirubin levels compared to zero out of 41 given chloroquine. It should be noted, however, that this study used pyronaridine monotherapy, and a higher dose than that which is currently recommended. The report did not give any further details of the extent of the increase.

As an indication of the magnitude of ALT increases, the highest reported ALT values in individual studies were 612 IU/L in [@CD006404-bbs2-0007] and 1229 IU/L in [@CD006404-bbs2-0008]. These were in individual patients, and are not indicative of the population as a whole. The study with the longest follow‐up recruited 180 participants ([@CD006404-bbs2-0002]). In the 60 participants receiving pyronaridine‐artesunate, observed increases in the median ALT and AST values had returned to baseline by day 14, and no clinical consequences of these liver enzyme increases were reported over one year of follow‐up. None of the 60 participants experienced raised ALT or AST \> 5 x ULN. It should be noted, however, that this was a study of pyronaridine‐artesunate plus primaquine, which could impact the findings. [@CD006404-bbs2-0008] reported one case in which raised ALT occurred with raised bilirubin in a two‐year old girl. The safety monitoring board concluded that this event was an acute hepatocellular liver injury, and was reported as a serious adverse event ([Table 10](#CD006404-tbl-0010){ref-type="table"}).

#### Other adverse events {#CD006404-sec4-0039}

We have summarized all other reported adverse events in [Analysis 4.10](#CD006404-fig-00410){ref-type="fig"}. To enable graphical display of these adverse events by [@CD006404-bbs2-0044] system organ class and higher level term, we present the results in a forest plot based on meta‐analysed subtotals in [Figure 5](#CD006404-fig-0005){ref-type="fig"}, based on PRISMA guidance ([@CD006404-bbs2-0064]). There was a lower risk of electrocardiograph (ECG) abnormality, including QT prolongation, with pyronaridine‐artesunate compared to each of the other antimalarials used as comparator drugs. A summary of the proportion of participants experiencing ECG abnormalities in each treatment group is provided in [Table 13](#CD006404-tbl-0013){ref-type="table"}. The greatest differences were seen in the [@CD006404-bbs2-0008] study when pyronaridine‐artesunate was compared to artemether‐lumefantrine and artesunate‐amodiaquine. The rates of observed QT prolongation were much higher in this study compared to other included studies.Figure 5A comparison of adverse events following treatment with pyronaridine‐artesunate versus other antimalarials, based on the reporting guidelines in PRISMA harms ([@CD006404-bbs2-0064]). Adverse events are categorized according to [@CD006404-bbs2-0044] system organ class and higher level terms. Where specific lower level terms were reported, we have used footnotes to indicate the condition described. Where trials reported more than one lower level term belonging to the same higher level term, we reported the lower level term with the highest frequency. ^a^Includes basophilia and monocytosis. ^b^Asymptomatic unifocal ventricular ectopics. ^c^Includes dizziness and palpitations. ^d^Ear pain. ^e^\"Chills\". ^f^Influenza‐like illness. ^g^Chest pain. ^h^Prolonged QTc, t wave inversion. ^i^Elevated CPK. ^j^Weight decreased. ^k^Thrombocytopaenia. ^l^Hypoalbuminaemia. ^m^Raised creatinine. ^n^Neck pain. ^o^Throat pain, cold, postnasal drip. ^p^Dark urine.Table 5Pyronaridine‐artesunate (PY‐AS) versus other antimalarials: electrocardiogram (ECG) abnormalities**Comparator drugTrialPyronaridine‐artesunateComparatorECG abnormalitiesNumber of participantsECG abnormalitiesNumber of participants**Artemether‐lumefantrine[@CD006404-bbs2-0008]5567399671Amodiaquine‐artesunate[@CD006404-bbs2-0008]3466991668Chloroquine[@CD006404-bbs2-0003]^a^12286228[@CD006404-bbs2-0016]^a^015115Dihydroartemisinin‐piperaquine or artesunate alone[@CD006404-bbs2-0002]^b^0601120Total9016451981702[^10]

For most types of adverse event, rates were similar between pyronaridine‐artesunate and comparators. Differences observed included the following.

Lower risk of cardiac symptoms. This category included dizziness and palpitations. The difference observed related to high instances of dizziness in the control group (mefloquine plus artesunate) in one study ([@CD006404-bbs2-0007]).Lower risk of pruritis. This occurred in comparisons to chloroquine, for which pruritis is a commonly recognized adverse event.Higher risk of diarrhoea: most cases of diarrhoea were contributed by one study, which was a monotherapy study using higher doses of pyronaridine than currently recommended ([@CD006404-bbs2-0004]).

Discussion {#CD006404-sec1-0006}
==========

Summary of main results {#CD006404-sec2-0011}
-----------------------

See [Table 1](#CD006404-tbl-0001){ref-type="table"}; [Table 2](#CD006404-tbl-0002){ref-type="table"}; [Table 3](#CD006404-tbl-0003){ref-type="table"}; [Table 4](#CD006404-tbl-0004){ref-type="table"}.

### Summary of efficacy findings {#CD006404-sec3-0030}

Overall, pyronaridine‐artesunate appears to have similar efficacy to other artemisinin‐based combination therapies (ACTs) (artemether‐lumefantrine, artesunate‐amodiaquine, mefloquine plus artesunate). In most included trials, pyronaridine‐artesunate had a lower than 5% PCR‐adjusted treatment failure rate at day 28 and day 42.

Treatment with pyronaridine‐artesunate may lead to fewer PCR‐adjusted failures at day 28 compared to artemether‐lumefantrine, artesunate‐amodiaquine, and mefloquine plus artesunate (low‐certainty evidence). In all these instances, the CIs cross the line of no effect.

Treatment with pyronaridine‐artesunate may lead to fewer PCR‐unadjusted failures at day 28 compared to artemether‐lumefantrine (low certainty evidence), and probably leads to fewer failures compared to artesunate‐amodiaquine and mefloquine plus artesunate (moderate‐certainty evidence). The PCR‐unadjusted outcome reflects the post‐treatment effect of the drug in preventing new infections.

Pyronaridine‐artesunate may have little or no difference on the rate of PCR‐adjusted failure at day 42 compared to artemether‐lumefantrine or artesunate‐amodiaquine (low‐certainty evidence), but may lead to higher rates of failure than mefloquine plus artesunate (low‐certainty evidence).

Pyronaridine‐artesunate may lead to a lower rate of PCR‐unadjusted treatment failure at day 42 compared to artemether‐lumefantrine (low‐certainty evidence), suggesting that the drug combination may reduce the likelihood of reinfection during the treatment period. Pyronaridine may little or no difference compared to mefloquine plus artesunate (low‐certainty evidence), and probably makes little or no difference compared to artesunate‐amodiaquine (moderate‐certainty evidence).

### Summary of safety findings {#CD006404-sec3-0031}

Raised ALT \> 5 x ULN is more frequent with pyronaridine‐artesunate compared to other antimalarials (high‐certainty evidence). Raised AST \> 5 x ULN is probably also more frequent (moderate‐certainty evidence), but the CI crosses the line of no effect. There is probably little or no difference for raised bilirubin \> 2.5 x ULN between pyronaridine‐artesunate and other antimalarials (moderate‐certainty evidence). There was one reported case in which raised ALT occurred with raised bilirubin. Qualitative evidence from one trial, with a cohort of 180 participants and a follow‐up of one year, indicated that raised liver enzymes were not prolonged and did not lead to clinical sequelae, though it should be noted that pyronaridine‐artesunate was administered concurrently with primaquine.

ECG abnormalities were less commonly seen with pyronaridine‐artesunate compared to other antimalarials. For the remaining safety outcomes, there appears to be little or no difference in the safety of pyronaridine‐artesunate compared to other ACTs (artemether‐lumefantrine, artesunate‐amodiaquine, mefloquine plus artesunate, dihydroartemisinin‐piperaquine) or non‐ACT antimalarials (artesunate alone, chloroquine).

Overall completeness and applicability of evidence {#CD006404-sec2-0012}
--------------------------------------------------

### Completeness and applicability of efficacy findings {#CD006404-sec3-0032}

Five trials contributed 5711 participants to quantitative synthesis for efficacy analyses in this review. There were 4465 participants from 13 trial sites in Africa (Burkina Faso, DRC, Gabon, Cote d\'Ivoire, Kenya, Mali, Tanzania, The Gambia, Ghana, Mozambique, Senegal, Guinea, Mali), and 1246 participants from five sites in Asia (the Philippines, Cambodia, Indonesia, Thailand, Vietnam). The large number of included sites broadens the applicability of the efficacy findings. The actual number of participants recruited at country level was small, precluding evaluation of efficacy at country level.

A key limitation on the applicability of review findings on efficacy is the age of the participants, as the included trials mostly recruited older children and adults. The two new studies included in the efficacy analysis in this update have contributed an additional 375 children under five years who received pyronaridine‐artesunate and 409 who received comparator drugs. However, the total number of participants definitively aged less than five years remains at just 527 in the pyronaridine‐artesunate arm and 472 in the comparator arm.

Trials additionally reported a number of outcomes relating to fever clearance, parasite clearance, and gametocyte carriage, which did not form a priori outcomes for this version of the review, in a change to the previously published protocol. We encountered different modes of reporting these outcomes, different units of measurement, and incomplete reporting of these outcomes. This limits the contribution of these outcomes to the evidence.

### Completeness and applicability of safety findings {#CD006404-sec3-0033}

Eight trials contributed to quantitative synthesis for key safety outcomes in this review (serious adverse events and liver function tests), and a further two trials contributed data to an analysis of all safety outcomes. All trials contributing to the safety meta‐analysis excluded participants with baseline hepatic impairment, and most trials listed viral hepatitis as a specific exclusion criterion. Similarly, [@CD006404-bbs2-0008] excluded patients with raised liver enzymes from second and subsequent treatments. Screening for baseline hepatic impairment, or for hepatic impairment during treatment, may not be feasible in many malaria‐endemic settings where resources are limited. This may limit the applicability of the findings.

Four trials explicitly listed HIV as an exclusion criterion ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0008]; [@CD006404-bbs2-0017]). Such exclusions represent standard practice for phase III trials. Given the high seroprevalence of such conditions in malaria‐endemic areas, this may limit the applicability of the safety findings. However, there was no reported screening for these conditions in any of the trials, meaning that it is likely that some patients with undiagnosed HIV were included. In a safety study in healthy volunteers ([@CD006404-bbs2-0047]), of 17 healthy volunteers receiving pyronaridine‐artesunate and ritonavir, five volunteers experienced ALT \> 3 x ULN. The WHO recommends ritonavir as part of second‐line antiretroviral therapy. Thus a commonly prescribed antiretroviral may increase the risk of raised ALT.

### Certainty of the evidence {#CD006404-sec3-0034}

We assessed the certainty of the evidence in this review using the GRADE approach and presented it in [Table 1](#CD006404-tbl-0001){ref-type="table"}, [Table 2](#CD006404-tbl-0002){ref-type="table"}, [Table 3](#CD006404-tbl-0003){ref-type="table"}, and [Table 4](#CD006404-tbl-0004){ref-type="table"}.

With respect to the efficacy of pyronaridine‐artesunate, the studies included in this review provided moderate‐ to low‐certainty evidence due to inconsistency, with frequent quantitative and qualitative heterogeneity between studies, and indirectness, given that children under five years are under‐represented (especially in Asia).

With respect to the safety of pyronaridine‐artesunate, we judged the certainty of evidence in relation to raised ALT to be high, and did not downgrade for imprecision, as although the CI is wide, there were few events. We found moderate‐certainty evidence that pyronaridine‐artesunate increases the proportion of patients experiencing raised AST \> 5 x ULN, and moderate‐certainty evidence that treatment has little or no difference on the proportion of patients experiencing raised bilirubin \> 2.5 x ULN. We downgraded both outcomes for imprecision.

Potential biases in the review process {#CD006404-sec2-0013}
--------------------------------------

This represents the third update of this review. For this review we repeated the screening process, increasing the likelihood that we identified all relevant studies.

The largest included trial in this review, [@CD006404-bbs2-0008], did not randomize patients to all comparisons at all sites, and we were unable to obtain disaggregated data for all outcomes at all sites. However, we were able to do so for the outcomes most pertinent to this review (efficacy and liver function data) so do not consider that this introduces significant bias to the review process.

As shown in [Table 9](#CD006404-tbl-0009){ref-type="table"}, different trial authors used different grading for the severity of adverse events. Most trial authors considered ALT \> 5 x ULN as important, and reported at this threshold. The three studies which reported at a lower threshold recorded zero events, so we retained these in the analysis for completeness ([@CD006404-bbs2-0002]; [@CD006404-bbs2-0006]; [@CD006404-bbs2-0016]). [@CD006404-bbs2-0001] reported at a higher threshold, and so may under‐detect events. When we performed a sensitivity analysis excluding these four trials, the risk ratio (RR) was similar ([Analysis 4.9](#CD006404-fig-00409){ref-type="fig"}). The reader should note that the grading for raised ALT does not correspond with international definitions for drug‐induced liver injury ([@CD006404-bbs2-0028]; [Appendix 1](#CD006404-sec2-0015){ref-type="app"}). Similarly, the thresholds for raised bilirubin also differed, both from each other and from the 2 x ULN used in international definitions of moderate or severe drug‐induced liver injury ([@CD006404-bbs2-0028]; [Appendix 1](#CD006404-sec2-0015){ref-type="app"}). As we are unable to provide case‐by‐case analysis for raised ALT \> 5 x ULN, we cannot exclude the possibility that in some instances these occurred in conjunction with symptoms of bilirubin \> 2 x ULN (given that the reported threshold was 2.5 in most studies). Qualitative synthesis did not suggest this was the case.

We had planned to conduct a sensitivity analysis altering the denominator for the efficacy outcomes according to [Appendix 4](#CD006404-sec2-0018){ref-type="app"}. However, we were unable to reliably extract data pertinent to missing or indeterminate PCR values. As PCR is unlikely to differentially misclassify recrudescences as reinfections between comparison groups, we do not feel this is likely to introduce bias to the main outcome of PCR‐adjusted treatment failure.

For the safety analysis we used [@CD006404-bbs2-0044] to create analogous definitions to allow comparison. This may lead to misclassification and loss of detail. However, we feel that the overview is more useful and meaningful to the clinical reader. The methodology of this review is not a primary adverse effects review, and as such does not include safety data from non‐comparative or non‐randomized studies, which such a review might include. This limits the depth to which this review can comment on the extent and implications of safety findings, but does not effect the certainty of the evidence presented.

Agreements and disagreements with other studies or reviews {#CD006404-sec2-0014}
----------------------------------------------------------

Our search identified an individual patient data analysis published by authors from Medicines for Malaria Venture and Shin Poong Pharmaceuticals, who developed the pyronaridine‐artesunate combination ([@CD006404-bbs2-0035]). The efficacy analysis in [@CD006404-bbs2-0035] included four of the RCTs included in our review ([@CD006404-bbs2-0001]; [@CD006404-bbs2-0003]; [@CD006404-bbs2-0007]; [@CD006404-bbs2-0017]). The safety analysis included an additional two studies: a non‐randomized dose‐finding study excluded from this review ([@CD006404-bbs2-0026]), and a randomized dose‐finding study that was published as a conference abstract which assessed pyronaridine‐artesunate without a comparator ([@CD006404-bbs2-0024]). This integrated analysis is not a formal systematic review, and as such did not have an a priori protocol or a formal search strategy. It did not make assessments of risk of bias. It is unclear whether the authors have included all potentially relevant studies or whether it represents a convenience sample of available data at the time of the analysis. The safety findings of this integrated analysis do not report relative risks or anticipated absolute effects of raised ALT, instead reporting incidence at day three and day seven. The day seven incidence of 0.9% (24/2709) is similar to our anticipated absolute effect of 0.8%.

Our review agrees with the conclusion from this integrated analysis ([@CD006404-bbs2-0035]), that pyronaridine‐artesunate has good efficacy for uncomplicated *P falciparum* malaria. The authors conclude that pyronaridine‐artesunate was well tolerated with a similar adverse event profile to comparators, and note that pyronaridine‐artesunate was associated with transient increases in transaminases in a relatively small proportion of patients, although do not caveat this statement with reference to the exclusion criteria within the clinical trials. When interpreting the conclusion in [@CD006404-bbs2-0035], readers should consider that the further data from [@CD006404-bbs2-0008] excluded participants who had raised liver enzyme events on first treatment from any subsequent treatments, and this may limit applicability.

Authors\' conclusions {#CD006404-sec1-0007}
=====================

Pyronaridine‐artesunate was efficacious against uncomplicated *P falciparum* malaria, achieved a PCR‐adjusted treatment failure rate of \< 5% at days 28 and 42, and may be at least as good as or better than existing artemisinin‐based combination therapies (ACTs).Pyronaridine‐artesunate causes a three‐fold increase in the risk of raised ALT \> 5 x ULN. This meets clinical chemistry criteria for drug‐induced liver injury ([@CD006404-bbs2-0028]; [Appendix 1](#CD006404-sec2-0015){ref-type="app"}). In the absence of raised bilirubin \> 2 x ULN, and in the absence of symptoms, this corresponds to mild drug‐induced liver injury only. There was one reported case in which raised ALT occurred with raised bilirubin, meeting criteria for moderate drug‐induced liver injury.We conclude that although raised ALT is a safety signal indicating a theoretical risk of severe drug‐induced liver injury, no such cases have been reported amongst over 6000 otherwise healthy trial participants to date. As such, the raised ALT may reflect a capacity for pyronaridine‐artesunate to cause only mild, asymptomatic, and reversible injury. [@CD006404-bbs2-0062] guidelines stated that pyronaridine‐artesunate may be considered in areas of multiple drug resistance. Our review indicates that this is an appropriate recommendation, as the benefit in this clinical scenario clearly outweighs a theoretical risk.The findings of this review cannot fully inform a risk‐benefit assessment for an unselected population. Readers should remain aware of this uncertainty when considering use of pyronaridine‐artesunate in patients with known or suspected pre‐existing liver dysfunction, and when co‐administering with other medications which may cause liver dysfunction.Raised ALT \> 5 x ULN is a safety signal which warrants further evaluation in cohort studies. Of note, Shin Poong Pharmaceutical Company Ltd and Medicines for Malaria Venture are conducting an ongoing hepatic safety study ([@CD006404-bbs2-0048]). This aims to recruit 8572 malaria episodes and will analyse safety in people with baseline ALT elevations.There is limited published data in children aged less than five years of age. [@CD006404-bbs2-0048] intends to recruit a greater number of children who are \< 1 year of age, which may help redress this.
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[@CD006404-bbs2-0028] is a consensus statement from an Expert Working Group of clinicians and scientists on the case definition of drug‐induced liver injury. The criteria are as follows.

Clinical chemistry criteria for drug‐induced liver injury {#CD006404-sec3-0035}
=========================================================

Any one of the following.

More than or equal to five‐fold elevation above the ULN for ALT.More than or equal to two‐fold elevation above the ULN for ALP (particularly with accompanying elevations in concentrations of 5′‐nucleotidase or γ‐glutamyl transpeptidase in the absence of known bone pathology driving the rise in ALP level).More than or equal to three‐fold elevation in ALT concentration and simultaneous elevation of bilirubin concentration exceeding 2 × ULN.

Drug‐induced liver injury severity index {#CD006404-sec3-0036}
========================================

**CategorySeverityDescription**1MildElevated ALT/ALP concentration reaching clinical chemistry criteria for drug‐induced liver injury, but bilirubin concentration \< 2 × ULN2ModerateElevated ALT/ALP concentration reaching criteria for drug‐induced liver injury, and bilirubin concentration ≥ 2 × ULN, or symptomatic hepatitis3SevereElevated ALT/ALP concentration reaching criteria for drug‐induced liver injury, bilirubin concentration ≥ 2× ULN, and one of the following.\
International normalized ratio ≥ 1.5Ascites and/or encephalopathy, disease duration \< 26 weeks, and absence of underlying cirrhosisOther organ failure considered to be due to drug‐induced liver injury4Fatal or transplantationDeath or transplantation due to drug‐induced liver injury

Abbreviations: ALP: alkaline phosphatase; ALT: alanine aminotransferase; ULN: upper limit of normal.

**Search setCIDG SR^a^CENTRALMEDLINE^b^Embase^b^LILACS^b^**1MalariaMalaria ti, ab, kwMalaria ti, ab, MeshMalaria.mp Emtreemalaria2pyronaridinePyronaridine ti, ab, kw\"pyronaridine\"ti, ab, Supplementary Conceptpyronaridine/ or artesunate plus pyronaridine/ or pyronaridine.mp.pyronaridine3pyramaxPyramax ti, ab, kw\"Naphthyridines\" MeshPyramax.mppyramax42 or 32 or 3Pyramax ti, ab2 or 32 or 351 and 41 and 42 or 3 or 41 and 41 and 46------1 and 5---

^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane ([@CD006404-bbs2-0041]).

**Potential biasAuthors\' judgement^a^**Random sequence generation (selection bias)High -- not randomized or quasi‐randomized\
Unclear -- states \"randomized\", but does not report method\
Low -- describes method of randomizationAllocation concealment (selection bias)High -- not concealed, open‐label trial for individually randomized, method of concealment not adequate\
Unclear -- details of method not reported or insufficient details\
Low -- central allocation, sequentially numbered opaque sealed envelopesBlinding (performance bias and detection bias)High -- personnel, participants or outcome assessors not blinded\
Unclear -- no details reported, insufficient details reported\
Low -- personnel, participants and outcome assessors blindedIncomplete outcome data (attrition bias)High -- losses to follow‐up not evenly distributed across intervention and control group\
Unclear ‐ no details reported, insufficient details reported\
Low -- losses to follow‐up evenly distributed across groups, reasons for loss to follow‐up and exclusions clearly statedSelective reporting (reporting bias)High -- did not fully report measured or relevant outcomes\
Unclear -- not enough information reported to judge\
Low -- all stated outcomes reportedOther biasHigh -- other source of bias identified by review authors\
Low -- no obvious other source of bias of concern to review authorsAdverse event monitoring (detection bias)High -- passive methods relying on spontaneous patient report only, undefined adverse events\
Unclear -- not enough information reported to judge\
Low -- key adverse events defined, prespecified active detection methodIncomplete adverse event reporting (reporting bias)High -- adverse event severity undefined, combination of treatment groups, post hoc cut‐offs for reporting adopted\
Unclear -- not enough information reported to judge\
Low -- clear reporting on important adverse events with numerical data by intervention group

^a^Indicative reasons for judgements only; this list is not intended to be exhaustive.

**Analysis^a^ParticipantsPCR^b^‐unadjustedPCR‐adjustedNumeratorDenominatorNumeratorDenominator**Primary analysisExclusions after enrolmentExcluded^c^ExcludedExcludedExcludedMissing or indeterminate PCRIncluded as failuresIncludedExcludedExcludedNew infectionsIncluded as failuresIncludedExcludedExcludedSensitivity analysis 1^d^As 'Primary analysis\' except: missing or indeterminate PCR------Included as failuresIncludedSensitivity analysis 2^e^As 'Sensitivity analysis 1\' except: new infections------Included as successesIncludedSensitivity analysis 3^f^As 'Sensitivity analysis 2\' except: exclusions after enrolmentIncluded as failuresIncludedIncluded as failuresIncludedSensitivity analysis 4^g^As 'Sensitivity analysis 2\' except: exclusions after enrolmentIncluded as successesIncludedIncluded as successesIncluded

^a^Remove participants that did not satisfy the inclusion criteria after randomization from all calculations. ^b^PCR: polymerase chain reaction. ^c^'Excluded\' means removed from the calculation. ^d^To reclassify all indeterminate or missing PCR results as treatment failures in the PCR‐adjusted analysis. ^e^To reclassify all PCR‐confirmed new infections as treatment successes in the PCR‐adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have gone on to develop a recrudescence after the new infection). ^f^To reclassify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR‐unadjusted total failure this represents a true worse‐case scenario. ^g^To reclassify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes.

Comparison 1Pyronaridine‐artesunate versus artemether‐lumefantrineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Total failure: day 42 (PCR‐adjusted)](#CD006404-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 1 Total failure: day 42 (PCR‐adjusted).72575Risk Ratio (M‐H, Random, 95% CI)0.86 \[0.49, 1.51\][2 Total failure: day 28 (PCR‐adjusted)](#CD006404-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 2 Total failure: day 28 (PCR‐adjusted).73068Risk Ratio (M‐H, Random, 95% CI)0.59 \[0.26, 1.31\][3 Total failure: day 28 (unadjusted)](#CD006404-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 3 Total failure: day 28 (unadjusted).73149Risk Ratio (M‐H, Random, 95% CI)0.27 \[0.13, 0.58\][4 Total failure: day 42 (unadjusted)](#CD006404-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 4 Total failure: day 42 (unadjusted).73080Risk Ratio (M‐H, Random, 95% CI)0.61 \[0.46, 0.82\][5 Early treatment failure](#CD006404-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 5 Early treatment failure.73149Risk Ratio (M‐H, Fixed, 95% CI)2.53 \[0.12, 52.39\][6 Serious adverse events](#CD006404-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 6 Serious adverse events.32004Risk Ratio (M‐H, Fixed, 95% CI)0.90 \[0.19, 4.22\][7 Adverse events leading to withdrawal](#CD006404-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 7 Adverse events leading to withdrawal.32004Risk Ratio (M‐H, Fixed, 95% CI)1.41 \[0.68, 2.90\][8 First treatment, ALT increase \> 5 × ULN](#CD006404-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 8 First treatment, ALT increase \> 5 × ULN.73327Risk Ratio (M‐H, Fixed, 95% CI)2.92 \[1.15, 7.41\][9 First treatment, AST increase \> 5 × ULN](#CD006404-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 9 First treatment, AST increase \> 5 × ULN.73327Risk Ratio (M‐H, Fixed, 95% CI)2.20 \[0.83, 5.82\][10 First treatment, bilirubin increase \> 2.5 × ULN](#CD006404-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 10 First treatment, bilirubin increase \> 2.5 × ULN.63130Risk Ratio (M‐H, Fixed, 95% CI)0.82 \[0.33, 2.04\][11 Subsequent treatment(s), ALT increase \> 5 × ULN](#CD006404-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 11 Subsequent treatment(s), ALT increase \> 5 × ULN.4865Risk Ratio (M‐H, Random, 95% CI)2.54 \[0.49, 13.10\][12 Subsequent treatment(s), AST increase \> 5 × ULN](#CD006404-fig-00112){ref-type="fig"}Analysis 1.12Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 12 Subsequent treatment(s), AST increase \> 5 × ULN.4865Risk Ratio (M‐H, Random, 95% CI)1.88 \[0.50, 7.06\][13 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN](#CD006404-fig-00113){ref-type="fig"}Analysis 1.13Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 13 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN.4865Risk Ratio (M‐H, Random, 95% CI)0.77 \[0.16, 3.63\][14 Paediatric trials ‐ total failure: day 28 (PCR‐adjusted)](#CD006404-fig-00114){ref-type="fig"}Analysis 1.14Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 14 Paediatric trials ‐ total failure: day 28 (PCR‐adjusted).2684Risk Ratio (M‐H, Random, 95% CI)1.02 \[0.13, 7.84\][15 Paediatric trials ‐ total failure: day 42 (PCR‐adjusted)](#CD006404-fig-00115){ref-type="fig"}Analysis 1.15Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 15 Paediatric trials ‐ total failure: day 42 (PCR‐adjusted).2558Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.41, 2.59\][16 Paediatric trials ‐ total failure: day 28 (unadjusted)](#CD006404-fig-00116){ref-type="fig"}Analysis 1.16Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 16 Paediatric trials ‐ total failure: day 28 (unadjusted).2693Risk Ratio (M‐H, Random, 95% CI)0.77 \[0.50, 1.18\][17 Paediatric trials ‐ total failure: day 42 (unadjusted)](#CD006404-fig-00117){ref-type="fig"}Analysis 1.17Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 17 Paediatric trials ‐ total failure: day 42 (unadjusted).2654Risk Ratio (M‐H, Random, 95% CI)0.99 \[0.74, 1.33\][18 Paediatric trials ‐ first treatment, ALT increase \> 5 × ULN](#CD006404-fig-00118){ref-type="fig"}Analysis 1.18Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 18 Paediatric trials ‐ first treatment, ALT increase \> 5 × ULN.2732Risk Ratio (M‐H, Fixed, 95% CI)0.51 \[0.03, 8.06\][19 Paediatric trials ‐ first treatment, AST increase \> 5 × ULN](#CD006404-fig-00119){ref-type="fig"}Analysis 1.19Comparison 1 Pyronaridine‐artesunate versus artemether‐lumefantrine, Outcome 19 Paediatric trials ‐ first treatment, AST increase \> 5 × ULN.2732Risk Ratio (M‐H, Fixed, 95% CI)1.52 \[0.16, 14.52\]

Comparison 2Pyronaridine‐artesunate versus artesunate‐amodiaquineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Total failure: day 28 (PCR‐adjusted)](#CD006404-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 1 Total failure: day 28 (PCR‐adjusted).61245Risk Ratio (M‐H, Random, 95% CI)0.55 \[0.11, 2.77\][2 Total failure: day 42 (PCR‐adjusted)](#CD006404-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 2 Total failure: day 42 (PCR‐adjusted).61091Risk Ratio (M‐H, Random, 95% CI)0.98 \[0.20, 4.83\][3 Total failure: day 28 (unadjusted)](#CD006404-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 3 Total failure: day 28 (unadjusted).61257Risk Ratio (M‐H, Random, 95% CI)0.49 \[0.30, 0.81\][4 Total failure: day 42 (unadjusted)](#CD006404-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 4 Total failure: day 42 (unadjusted).61235Risk Ratio (M‐H, Random, 95% CI)0.98 \[0.78, 1.23\][5 First treatment, ALT increase \> 5 × ULN](#CD006404-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 5 First treatment, ALT increase \> 5 × ULN.61317Risk Ratio (M‐H, Fixed, 95% CI)1.41 \[0.28, 7.09\][6 First treatment, AST increase \> 5 × ULN](#CD006404-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 6 First treatment, AST increase \> 5 × ULN.61317Risk Ratio (M‐H, Fixed, 95% CI)0.40 \[0.08, 2.07\][7 First treatment, bilirubin increase \> 2.5 × ULN](#CD006404-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 7 First treatment, bilirubin increase \> 2.5 × ULN.61317Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.06, 15.76\][8 Subsequent treatment(s), ALT increase \> 5 × ULN](#CD006404-fig-00208){ref-type="fig"}Analysis 2.8Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 8 Subsequent treatment(s), ALT increase \> 5 × ULN.6784Risk Ratio (M‐H, Fixed, 95% CI)1.93 \[0.48, 7.76\][9 Subsequent treatment(s), AST increase \> 5 × ULN](#CD006404-fig-00209){ref-type="fig"}Analysis 2.9Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 9 Subsequent treatment(s), AST increase \> 5 × ULN.6784Risk Ratio (M‐H, Fixed, 95% CI)1.80 \[0.49, 6.62\][10 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN](#CD006404-fig-00210){ref-type="fig"}Analysis 2.10Comparison 2 Pyronaridine‐artesunate versus artesunate‐amodiaquine, Outcome 10 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN.6784Risk Ratio (M‐H, Fixed, 95% CI)1.80 \[0.33, 9.83\]

Comparison 3Pyronaridine‐artesunate versus mefloquine plus artesunateOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Total failure: day 28 (PCR‐adjusted)](#CD006404-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 1 Total failure: day 28 (PCR‐adjusted).11117Risk Ratio (M‐H, Random, 95% CI)0.37 \[0.13, 1.05\][2 Total failure: day 42 (PCR‐adjusted)](#CD006404-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 2 Total failure: day 42 (PCR‐adjusted).11037Risk Ratio (M‐H, Random, 95% CI)1.80 \[0.90, 3.57\][3 Total failure: day 28 (unadjusted)](#CD006404-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 3 Total failure: day 28 (unadjusted).11120Risk Ratio (M‐H, Random, 95% CI)0.36 \[0.17, 0.78\][4 Total failure: day 42 (unadjusted)](#CD006404-fig-00304){ref-type="fig"}Analysis 3.4Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 4 Total failure: day 42 (unadjusted).11059Risk Ratio (M‐H, Random, 95% CI)0.84 \[0.54, 1.31\][5 Serious adverse events](#CD006404-fig-00305){ref-type="fig"}Analysis 3.5Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 5 Serious adverse events.11271Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.25, 3.97\][6 Adverse events leading to withdrawal](#CD006404-fig-00306){ref-type="fig"}Analysis 3.6Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 6 Adverse events leading to withdrawal.11271Risk Ratio (M‐H, Fixed, 95% CI)0.62 \[0.17, 2.31\][7 First treatment, ALT increase \> 5 × ULN](#CD006404-fig-00307){ref-type="fig"}Analysis 3.7Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 7 First treatment, ALT increase \> 5 × ULN.11271Risk Ratio (M‐H, Fixed, 95% CI)7.48 \[0.99, 56.45\][8 First treatment, AST increase \> 5 × ULN](#CD006404-fig-00308){ref-type="fig"}Analysis 3.8Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 8 First treatment, AST increase \> 5 × ULN.11271Risk Ratio (M‐H, Fixed, 95% CI)9.49 \[0.55, 162.64\][9 First treatment, bilirubin increase \> 2.5 × ULN](#CD006404-fig-00309){ref-type="fig"}Analysis 3.9Comparison 3 Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 9 First treatment, bilirubin increase \> 2.5 × ULN.11271Risk Ratio (M‐H, Fixed, 95% CI)3.49 \[0.43, 28.29\]

Comparison 4Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Serious adverse events](#CD006404-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 1 Serious adverse events.73941Risk Ratio (M‐H, Fixed, 95% CI)1.24 \[0.54, 2.84\][2 Adverse events leading to withdrawal](#CD006404-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 2 Adverse events leading to withdrawal.63911Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.58, 1.94\][3 First treatment, ALT increase \> 5 × ULN](#CD006404-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 3 First treatment, ALT increase \> 5 × ULN.146581Risk Ratio (M‐H, Fixed, 95% CI)3.34 \[1.63, 6.84\][4 First treatment, AST increase \> 5 × ULN](#CD006404-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 4 First treatment, AST increase \> 5 × ULN.146581Risk Ratio (M‐H, Fixed, 95% CI)1.80 \[0.89, 3.65\][5 First treatment, bilirubin increase \> 2.5 × ULN](#CD006404-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 5 First treatment, bilirubin increase \> 2.5 × ULN.136384Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.49, 2.18\][6 Subsequent treatment(s), ALT increase \> 5 × ULN](#CD006404-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 6 Subsequent treatment(s), ALT increase \> 5 × ULN.71649Risk Ratio (M‐H, Fixed, 95% CI)2.18 \[0.76, 6.27\][7 Subsequent treatment(s), AST increase \> 5 × ULN](#CD006404-fig-00407){ref-type="fig"}Analysis 4.7Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 7 Subsequent treatment(s), AST increase \> 5 × ULN.71649Risk Ratio (M‐H, Fixed, 95% CI)1.82 \[0.74, 4.44\][8 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN](#CD006404-fig-00408){ref-type="fig"}Analysis 4.8Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 8 Subsequent treatment(s), bilirubin increase \> 2.5 × ULN.71649Risk Ratio (M‐H, Fixed, 95% CI)1.13 \[0.42, 3.01\][9 Sensitivity analysis: first treatment, ALT increase \> 5 × ULN](#CD006404-fig-00409){ref-type="fig"}Analysis 4.9Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 9 Sensitivity analysis: first treatment, ALT increase \> 5 × ULN.105672Risk Ratio (M‐H, Fixed, 95% CI)4.07 \[1.83, 9.05\][10 Other adverse events](#CD006404-fig-00410){ref-type="fig"}Analysis 4.10Comparison 4 Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 10 Other adverse events.10Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only10.1 Blood and lymphatic: anaemias44517Risk Ratio (M‐H, Fixed, 95% CI)1.15 \[0.86, 1.54\]10.2 Blood and lymphatic: eosinophilic disorders22543Risk Ratio (M‐H, Fixed, 95% CI)1.29 \[0.86, 1.93\]10.3 Blood and lymphatic: leukocytoses22615Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.42, 1.37\]10.4 Blood and lymphatic: neutropaenias22616Risk Ratio (M‐H, Fixed, 95% CI)0.83 \[0.63, 1.10\]10.5 Cardiac: cardiac arrhythmias1180Risk Ratio (M‐H, Fixed, 95% CI)5.95 \[0.25, 143.93\]10.6 Cardiac: cardiac signs and symptoms52108Risk Ratio (M‐H, Fixed, 95% CI)0.57 \[0.37, 0.89\]10.7 Cardiac: myocardial disorders130Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.58\]10.8 Ear: ear disorders1197Risk Ratio (M‐H, Fixed, 95% CI)0.32 \[0.01, 7.69\]10.9 Gastrointestinal: diarrhoea (excl infective)4411Risk Ratio (M‐H, Fixed, 95% CI)2.56 \[1.10, 5.99\]10.10 Gastrointestinal: dyspeptic signs and symptoms130Risk Ratio (M‐H, Fixed, 95% CI)3.0 \[0.13, 68.26\]10.11 Gastrointestinal: GI and abdominal pains74544Risk Ratio (M‐H, Fixed, 95% CI)1.12 \[0.87, 1.45\]10.12 Gastrointestinal: nausea and vomiting symptoms95534Risk Ratio (M‐H, Fixed, 95% CI)0.91 \[0.71, 1.17\]10.13 General: asthenic conditions2653Risk Ratio (M‐H, Fixed, 95% CI)1.32 \[0.64, 2.75\]10.14 General: general signs and symptoms1535Risk Ratio (M‐H, Fixed, 95% CI)1.20 \[0.54, 2.70\]10.15 General: feelings and sensations1197Risk Ratio (M‐H, Fixed, 95% CI)4.75 \[0.23, 97.79\]10.16 General: febrile disorders2715Risk Ratio (M‐H, Fixed, 95% CI)1.39 \[0.65, 2.96\]10.17 General: pain and discomfort1197Risk Ratio (M‐H, Fixed, 95% CI)0.19 \[0.01, 3.91\]10.18 Infections and infestations: eye and eyelid130Risk Ratio (M‐H, Fixed, 95% CI)3.0 \[0.13, 68.26\]10.19 Infections and infestations: LRTI and lung23216Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.83, 1.11\]10.20 Infections and infestations: URTI75350Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.88, 1.20\]10.21 Investigations: ECG43347Risk Ratio (M‐H, Fixed, 95% CI)0.46 \[0.36, 0.58\]10.22 Investigations: skeletal/cardiac muscle analyses2636Risk Ratio (M‐H, Fixed, 95% CI)1.32 \[0.55, 3.15\]10.23 Investigations: physical exam130Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.58\]10.24 Investigations: platelet2565Risk Ratio (M‐H, Fixed, 95% CI)0.92 \[0.55, 1.56\]10.25 Investigations: protein1535Risk Ratio (M‐H, Fixed, 95% CI)0.67 \[0.36, 1.24\]10.26 Metabolism and nutrition: appetite disorders3683Risk Ratio (M‐H, Fixed, 95% CI)1.47 \[0.80, 2.68\]10.27 Metabolism and nutrition: hypoglycaemia conditions1535Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.50, 1.46\]10.28 Metabolism and nutrition: metabolic disorders12681Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.61, 1.29\]10.29 MSK and connective tissue: muscle pains31924Risk Ratio (M‐H, Fixed, 95% CI)1.40 \[0.97, 2.01\]10.30 MSK and connective tissue: pain and discomfort1197Risk Ratio (M‐H, Fixed, 95% CI)0.32 \[0.01, 7.69\]10.31 Nervous system: headaches96271Risk Ratio (M‐H, Fixed, 95% CI)1.09 \[0.90, 1.32\]10.32 Nervous system: sleep disturbance1180Risk Ratio (M‐H, Fixed, 95% CI)0.66 \[0.03, 15.99\]10.33 Nervous system: paraesthesias and dysasthesias130Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.58\]10.34 Respiratory: coughing and assoc symptoms66412Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.82, 1.19\]10.35 Respiratory: upper respiratory tract signs and symptoms3407Risk Ratio (M‐H, Fixed, 95% CI)1.80 \[0.32, 10.07\]10.36 Renal and urinary: urinary abnormalities1197Risk Ratio (M‐H, Fixed, 95% CI)1.90 \[0.18, 20.63\]10.37 Skin and subcutaneous tissue: dermatitis and eczema2276Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.15, 6.99\]10.38 Skin and subcutaneous tissue: pruritis2184Risk Ratio (M‐H, Fixed, 95% CI)0.25 \[0.13, 0.49\]10.39 Skin and subcutaneous tissue: rashes, eruptions, exanthems1197Risk Ratio (M‐H, Fixed, 95% CI)1.90 \[0.18, 20.63\]10.40 Skin and subcutaneous tissue: urticaria130Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.58\]10.41 Vascular: vascular hypotensive disorders130Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 7.58\]

**DateEventDescription**8 January 2019New citation required and conclusions have changedWe included four new studies: three published after the previous version of this review, [@CD006404-bbs2-0065], and one that was not identified in the previous review. During re‐extraction of data from the previous studies we used a transparent, itemized, and replicable procedure that differed from [@CD006404-bbs2-0065]. The inclusion of new studies has allowed a new comparison of pyronaridine‐artesunate and artesunate‐amodiaquine, and has led to changes in the certainty of the evidence in relation to the primary outcomes. This review update gives higher‐certainty evidence in relation to the effect of pyronaridine‐artesunate on raised alanine aminotransferase (ALT).8 January 2019New search has been performedThere is a new author team: Joseph Pryce, Paul Hine (new contact person).\
We use the term pyronaridine‐artesunate in preference to artesunate‐pyronaridine to reflect how most authors refer to the intervention. We updated the background to reflect changes in global epidemiology, current World Health Organization (WHO) guidelines, and other developments. We added the term 'pyramax\' to the search strategy.\
We replaced the quantitative analysis of secondary outcomes 'parasite clearance\', 'fever clearance\', and 'gametocyte carriage\' with a narrative synthesis, and comment on the reasons for doing so. We simplified the 'Adverse events\' outcomes to reflect that elevated liver function tests are a primary area of interest.\
We itemized the procedure for data extraction to ensure that the process is transparent and replicable in future review updates. We have added further commentary regarding the data extraction process. We simplified the 'Risk of bias\' assessment for adverse events. We abbreviated the content of tables to enable clear and succinct presentation. We incorporated risk of bias for adverse events assessments into the main 'Risk of bias\' tables. We added an appendix to summarize our 'Risk of bias\' assessment process.

Protocol first published: Issue 1, 2007 Review first published: Issue 3, 2014

**DateEventDescription**11 November 2008AmendedWe converted to the new review format with minor editing.

Differences between protocol and 2014 review {#CD006404-sec2-0021}
============================================

We stated in the protocol that we intended to assess the methods used to generate the allocation sequence and conceal allocation concealment as adequate, inadequate, or unclear according to [Jüni 2001](Jüni 2001), and note who was blinded to the interventions in each trial. However, since the introduction of [Review Manager 2011](Review Manager 2011), we made these assessments using the methods described in [Higgins 2011](Higgins 2011).

In keeping with the Cochrane Collaboration policy to use \'Summary of findings\' tables, which was introduced after publication of the protocol, we generated them using GRADE profiler ([GRADE 2008](GRADE 2008)) and interpreted the evidence for each outcome and comparison using the GRADE approach ([Schünemann 2008](Schünemann 2008)).

We revised the list of outcomes to reflect current WHO standards for assessing outcomes in antimalarial trials.

Although gametocyte carriage was not included as an outcome in the protocol, we included it as a secondary outcome due to its importance in malaria transmission.

In the protocol we stated that we intended to assess the effectiveness of pyronaridine both as a monotherapy and in combination with an artemisinin. However, we revised this to focus only on pyronaridine‐artemisinin combinations. In addition, due to concerns regarding pyronaridine\'s effect on the liver, assessment of the effects of the comparisons on liver function now include randomized comparisons in both falciparum and vivax malaria. Accordingly, we updated the background and methods sections considerably to reflect the changing scenario in malaria policies and epidemiology.

PT and HB joined the review team. Rajeev Aravindakshan withdrew from the team due to conflicting demands on his time.

Differences between protocol and 2018 review update {#CD006404-sec2-0022}
===================================================

There is a new author team: Joseph Pryce and Paul Hine.

We use the term pyronaridine‐artesunate in preference to artesunate‐pyronaridine to reflect how most authors refer to the intervention; we changed the title accordingly. We did not proceed with quantitative analysis of secondary outcomes 'parasite clearance\', 'fever clearance\', and 'gametocyte carriage\'. The original protocol did not clearly define these outcomes, including whether they refer to durations, rates, or proportions of patients at given time points. We encountered considerable heterogeneity in these measures between studies, and therefore present a narrative synthesis. We simplified the 'Adverse events\' outcomes to reflect areas which are of most interest.

We added the term 'pyramax\' to the search strategy. We simplified the assessment of risk of bias for adverse events.

Characteristics of included studies \[ordered by study ID\] {#CD006404-sec2-0023}
===========================================================

[@CD006404-bbs2-0001]MethodsRCT\
Duration: 1 year, November 2007 to November 2008ParticipantsChildren with *P falciparum* malaria\
Number: 535, randomized 2:1\
**Inclusion criteria**: age ≤ 12 years; bodyweight 5 kg ‐ 25 kg; fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; mixed *Plasmodium* infection; other clinically significant disorder; severe vomiting; severe diarrhoea; viral hepatitis/HIV; malnutrition; QTc ≥ 450 ms; other febrile conditions; hepatic impairment (AST/ALT \> 2.5x ULN); renal impairment; electrolyte imbalance; anaemia (Hb \< 8 g/dL); allergy to study drugs; antimalarial therapy in previous 2 weeks, investigational drug in previous 4 weeks; taking any drug metabolized by cytochrome enzyme CYP2D6; previous participation in pyronardine‐artesunate studies; pregnancy/lactation; unable to comply with follow‐up visits\
**Diagnosis**: microscopy (asexual parasite density 1000‐200,000/µL blood)\
Children under 5: 152 (pyronaridine‐artesunate); 64 (artemether‐lumefantrine)InterventionsPyronaridine‐artesunate granule formulation (60 mg:20 mg) once‐daily for 3 days. Dose according to bodyweight: 5 kg ‐ 9 kg one sachet; 9 kg ‐ 17 kg 2 sachets; 17 kg ‐ 25 kg, 3 sachets. Range = 6.7/2.2 mg/kg/dose to 13.3/4.4 mg/kg/doseArtemether‐lumefantrime crushed tablets (20 mg/120 mg) twice daily for 3 days at recommended intervals. Dose according to bodyweight: 5 kg ‐15 kg one tablet, 15 kg ‐25 kg 2 tablets. Range = 1.3/8.0 mg to 3.0/24.0 mg/kg/doseOutcomesACPR day 28 PCR‐adjustedACPR day 28 unadjustedACPR day 42 PCR‐adjustedACPR day 42 unadjustedParasite clearance time (from first dose to aparasitaemia)†, ‡Fever clearance time (from first dose to apyrexia)†, ‡Proportion of patients with parasite clearance on days 1, 2, and 3, ‡Proportion of patients with fever clearance on days 1, 2, and 3, ‡Gametocyte density, ‡Proportion of patients with gametocytesAdverse events (including laboratory and ECG abnormalities)\
†Two consecutive normal readings taken between 7 and 25 hours apart\
‡Not assessed in quantitative synthesis in this reviewNotesLocation: Africa (n = 514, 96%) and Asia (n = 21, 4%). Africa: Burkina Faso, DRC, Gabon, Côte d'Ivoire, Kenya, Mali. Asia: the Philippines\
Setting: Local hospitals and clinics\
Malaria endemicity: high\
Resistance profile: not described\
Source of funding: Medicines for Malaria Venture, Shin Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization scheduleAllocation concealment (selection bias)Low riskIndividually numbered treatment packs of similar appearance masked on allocationBlinding (performance bias and detection bias) All outcomesLow riskPatients not blinded (\"drugs given open‐label\")\
Clinical and parasitological assessments blindedIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskProspectively registered. Report includes all prestated outcomes of interestOther biasLow risk3 authors declared conflicting interests (employees of funders); blind to treatment allocationAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not fully describe method for detection of adverse events, includes biochemical and ECG monitoring.\
Authors do not give definitions of all adverse events.\
Uses higher ULN values for grading of hepatic enzyme severity compared to other studiesIncomplete adverse event reporting (reporting bias) Adverse eventsLow riskAll adverse events reported. Supplementary tables detail laboratory variables at each assessment[@CD006404-bbs2-0002]MethodsRCT\
Duration: 1 year, 4 months. March 2013 to July 2014ParticipantsAdult soldiers with *P vivax* malaria\
Number: 180\
**Inclusion criteria**: age 18 ‐ 65 years; travelled to NE Papua within 12 months; bodyweight 40 kg ‐ 90 kg\
**Exclusion criteria**: G6PD deficiency; *P falciparum* monoinfection, hospitalization, anaemia (Hb \< 7 g/dL), planned absence from military base; clinically significant disorders; QTc ≥ 450 ms; family history prolonged QTc/sudden death; concomitant drugs known to prolong QT; hepatic impairment (AST/ALT \> 2.5 x ULN); renal impairment; viral hepatitis; allergy to study drugs; previous participation; recent antimalarials\
**Diagnosis**: microscopy of *P vivax*, confirmed by a second microscopistInterventionsArtesunate tablets (200 mg day 0, 100 mg days 1‐6), followed by primaquinePyronaridine‐artesunate tablets (180 mg:60 mg) once‐daily for 3 days. Dose according to bodyweight: 24 kg ‐ 45 kg 2 tablets, 45 kg ‐ 65 kg 3 tablets, ≥ 65 kg 4 tablets. Concurrent primaquine.Dihydroartemisinin‐piperaquine tablets (40 mg:320 mg) once‐daily for 3 days. Dose according to bodyweight: \< 75 kg ‐ 3 tablets, ≥ 75 kg ‐ 4 tablets. Concurrent primaquine.OutcomesAdverse eventsRelapse of *P vivax\** (incidence density)\
\*Not assessed in quantitative synthesis in this reviewNotesLocation: Indonesia, in travellers returning from Papua\
Setting: army base\
Malaria endemicity: no known risk of malaria in study site\
Resistance profile: the infections were by the chloroquine‐resistant and primaquine‐tolerant Chesson‐like *P vivax* strains\
Source of funding: sponsored by the ALERT Asia Foundation (Indonesia), funded by Medicines for Malaria Venture (Switzerland)\
Follow‐up: 1 year***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Statistician block‐allocated treatment assignments by varying blocking number at random\"Allocation concealment (selection bias)Low riskSealed envelopeBlinding (performance bias and detection bias) All outcomesLow riskUnclear if participants or assessing clinicians were blinded.\
Parasitological assessments blindedIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskProspective registration, reports all a priori outcomesOther biasLow riskMMV played an advisory role, but had no role in study conduct or analysisAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not fully describe schedule for detection of adverse events, includes biochemical and ECG monitoring.\
Authors do not clearly define adverse events, including significant raise in hepatic enzymesIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskReports numbers of adverse events by grade, but do not define grading used[@CD006404-bbs2-0003]MethodsRCT\
Duration: 1 year, March 2007 to March 2008ParticipantsAdults and children with *P vivax* malaria\
Number: 456\
**Inclusion criteria**: age 3 ‐ 60 years; fever or history of fever within 24 hours; bodyweight 20 kg ‐ 90 kg\
**Exclusion criteria**: severe/complicated malaria; mixed *Plasmodium* infection; severe vomiting; other clinical condition recurring hospitalization; other clinically significant disorder; viral hepatitis/HIV; malnutrition; QTc ≥ 450 ms; other febrile conditions; hepatic impairment (AST/ALT \> 2.5 x ULN); renal impairment; anaemia (Hb \< 8 g/dL); allergy to study drugs; antimalarial therapy in previous 2 weeks (or antibacterial with antimalarial effect); investigational drug in previous 4 weeks; previous participation in pyronaridine‐artesunate studies; pregnancy/lactation; unable to comply with follow‐up visits\
**Diagnosis**: microscopy of *P vivax* (parasite density ≥ 250/mL blood, including \> 50% asexual parasites)InterventionsPyronaridine‐artesunate tablets (180 mg:60 mg) once‐daily for 3 days. Dose according to bodyweight: 20 kg ‐ 25 kg one tablet; 26 kg ‐ 44 kg two tablets; 65 kg ‐ 90 kg, 3 tablets. Range = 7.2/2.4 to 13.8/4.6 mg/kg/doseChloroquine 620 mg on day 0 and 1, and 310 mg on day 2. The chloroquine target dose for children was 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2OutcomesAdverse eventsCure rate day 14\*Cure rates day 21, 35, and 42\*Fever clearance time (from first dose to apyrexia)†\*Proportions afebrile and aparasitaemic on days 1, 2, and 3\*\
\*Not assessed in quantitative synthesis in this review\
†Two consecutive normal readings taken between 7 and 25 hours apartNotesLocation: Asia (Cambodia, India, Indonesia, and Thailand)\
Setting: local hospitals\
Malaria endemicity: high\
Resistance profile: not described\
Source of funding: Medicines for Malaria Venture, Shin Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization schemeAllocation concealment (selection bias)Low riskSealed opaque envelopesBlinding (performance bias and detection bias) All outcomesLow riskDoubly‐dummy ‐ study drug and matching placebo, packaged similarly\
All study investigators, laboratory technicians, and patients blind to treatment assignment\
Investigator calculated the appropriate dose and study drug was administered by a different member of staffIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskProspectively registered. Report includes all prestated outcomes of interestOther biasLow risk3 authors declared conflicting interests (employees of funders); blind to treatment allocationAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not fully describe method for detection of adverse events, but describe interval for ECG assessment. Authors do not give definitions of all adverse eventsIncomplete adverse event reporting (reporting bias) Adverse eventsLow riskAll‐cause adverse events enumerated. Report table only includes adverse events occurring in ≥ 2% (or ≥ 1% if judged to be drug‐related)[@CD006404-bbs2-0004]MethodsRCT\
Duration: 1 year, 1 month: April 1994 to May 1995ParticipantsAdults (\> 15 years) with *P falciparum* malaria\
Number: 96\
**Inclusion criteria**: fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; mixed *Plasmodium* infection; recent self‐medication; pregnancy\
**Diagnosis**: thin film microscopy of *P falciparum* (asexual parasite density \> 5000/µL blood)InterventionsPyronaridine: 32 mg/kg in divided doses over 3 days: 16 mg/kg on day 0; 8 mg/kg on days 1 and 2Chloroquine: 25 mg/kg in divided doses over 3 days: 10 mg/kg on days 0 and 1; 5 mg/kg on day 2OutcomesAdverse eventsFever clearance (time from onset of treatment until temp remained below 37.5°C)\*Parasite clearance (time until the first negative tick blood smear, with subsequent smears negative)\*Early treatment failure\*Parasitaemia on day 14\*Gametocyte carriage at day 14\*In vitro drug susceptibility\*\
\*Not assessed in quantitative synthesis in this reviewNotesLocation: Cameroon\
Setting: dispensary (outpatients)\
Malaria endemicity: high\
Resistance profile: 57% of isolates chloroquine‐resistant\
Source of funding: French Ministere de la Co‐operation (Grant 93A43); pyronaridine was supplied by the Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shangai, China\
Follow‐up: 14 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization (blocks of 10); from communication with authors recorded by previous version of this reviewAllocation concealment (selection bias)Low riskCentral randomization; from communication with authors recorded by previous version of this reviewBlinding (performance bias and detection bias) All outcomesLow riskBlinded, but tablets were different and patients treated with chloroquine suffered pruritis; from communication with authors recorded by previous version of this reviewIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusions; unlikely to have differentially influenced liver toxicity outcomes used in this reviewSelective reporting (reporting bias)Low riskTrial not prospectively registered, trial protocol not available. However, all outcomes stated in methods reportedOther biasLow riskNone identifiedAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not fully describe method for detection of adverse events. Authors do not give definitions of all adverse eventsIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskAuthors give brief narrative description of adverse events only. Report does not detail extent of elevation in liver transaminases or the proportions retested at day 14[@CD006404-bbs2-0005]MethodsRCT\
Duration not stated. Year 1996ParticipantsChildren (\< 15 years) with *P falciparum* malaria\
Number: 88\
**Inclusion criteria**: fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; mixed *Plasmodium* infection; recent self‐medication; pregnancy; anaemia (Hb \< 5g/dL), moderate to severe malnutrition.\
**Diagnosis**: thin film microscopy of *P falciparum* (asexual parasite density \> 5000/µL blood)InterventionsPyronaridine: 32 mg/kg in divided doses over 3 days: 16 mg/kg on day 0; 8 mg/kg on days 1 and 2Chloroquine: 25 mg/kg in divided doses over 3 days: 10 mg/kg on days 0 and 1; 5 mg/kg on day 2OutcomesAdverse eventsFever clearance (time from onset of treatment until temp remained below 37.5°C)\*Parasite clearance (time until the first negative tick blood smear, with subsequent smears negative)\*Early treatment failure\*Parasitaemia on day 14\*Gametocyte carriage at day 14\*\
\*Not assessed in quantitative synthesis in this reviewNotesLocation: Cameroon\
Setting: dispensary (outpatients)\
Malaria endemicity: high\
Resistance profile: 49% of isolates chloroquine‐resistant\
Source of funding: French Ministere de la Co‐operation (Grant 93A43); pyronaridine was supplied by the Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shangai, China\
Follow‐up: 14 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization (blocks of 10); from communication with authors recorded by previous version of this reviewAllocation concealment (selection bias)Low riskCentral randomization; from communication with authors recorded by previous version of this reviewBlinding (performance bias and detection bias) All outcomesLow riskBlinded, but tablets were different and patients treated with chloroquine suffered pruritis; from communication with authors recorded by previous version of this reviewIncomplete outcome data (attrition bias) All outcomesLow riskReport and subsequent correspondence from authors lists reasons for attrition and exclusions; unlikely to have differentially influenced liver toxicity outcomes used in this reviewSelective reporting (reporting bias)Low riskTrial not prospectively registered, trial protocol not available. However, all outcomes stated in methods reportedOther biasLow riskNone identifiedAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not fully describe method for detection of adverse events. Authors do not give definitions of all adverse eventsIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskAuthors give brief narrative description of adverse events only. Report does not detail extent of elevation in liver transaminases or the proportions retested at day 14[@CD006404-bbs2-0006]MethodsRCT\
Duration: 1 year, 5 months. October 2015 to June 2016, January 2017 to August 2017ParticipantsChildren with *P falciparum* malaria\
Number: 197\
**Inclusion criteria**: age 6 months ‐ 12 years; bodyweight ≥ 5 kg\
**Exclusion criteria**: severe/complicated malaria; non‐*falciparum*/mixed *Plasmodium* infection; other clinically significant disorder; malnutrition; hepatic impairment (AST/ALT not specified); renal impairment; anaemia (Hb \<6 g/dL); allergy to study drugs; current participation in other antimalarial study; previous participation in study, not available for follow‐up\
**Diagnosis**: microscopically‐confirmed *P falciparum* monoinfection (asexual parasite density 1000 µL‐200,000/µL)\
Children under 5: 31 (pyronardine‐artesunate); 31 (artemether‐lumefantrine)InterventionsPyronaridine‐artesunate granules (60 mg:20 mg) or tablets (180 mg:60 mg) once‐daily for 3 days. Dose according to bodyweight: 5 kg ‐ 8 kg one sachet, 8 kg ‐15 kg 2 sachets, 15 kg ‐ 20 kg 3 sachets, 20 kg ‐ 24 kg one tablet, 24 kg ‐ 45 kg 2 tabletsArtemether‐lumefantrine crushed tablets (20 mg/120 mg) twice daily for 3 days at recommended intervals. Dose according to bodyweight: 5 kg ‐ 15 kg one tablet, 15 kg ‐ 25 kg 2 tablets, 25 kg ‐ 35 kg 3 tablets, ≥ 35 kg 4 tabletsOutcomesACPR\* day 28 PCR‐adjustedACPR day 28 unadjustedACPR day 42 PCR‐adjustedACPR day 42 unadjustedParasite clearance time (from first dose to aparasitaemia)†, ‡Fever clearance time (from first dose to apyrexia)†\"Transmission potential to mosquitoes\" (undefined)‡Adverse events (including laboratory abnormalities)Proportion of patients with parasite clearance on days 1, 2, and 3, ‡Proportion of patients with fever clearance on days 1, 2, and 3, ‡\
\*Adequate clinical and parasitological response rate\
†Two consecutive normal readings taken between 7 and 25 hours apart\
‡Not assessed in quantitative synthesis in this reviewNotesLocation: Kenya\
Setting: Local clinic\
Malaria endemicity: high\
Resistance profile: not described\
Source of funding: EU FP7‐Health‐2013. 0‐1 Project "Translation of the direct‐on‐blood PCR‐NALFIA system into an innovative near point‐of‐care diagnostic for malaria" (DIAGMAL) \[Grant Number 601714\]\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization schedule provided by sponsorAllocation concealment (selection bias)Low riskSequentially numbered sealed opaque envelopesBlinding (performance bias and detection bias) All outcomesLow riskPatients probably not blinded (drugs were administered by pharmacy personnel aware of group assignments)\
Clincial and parasitological assessments performed by study staff blinded to treatment allocationIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskAuthors report fever clearance time which was not in trial registration document. Unlikely to introduce significant biasOther biasLow riskTarget recruitment not reached\
Shin Poong Pharmaceutical Company (Seoul, South Korea) provided pyronaridine--artesunate tablets and granules, but had no further role in study design, data collection, data analysis and writing of the reportAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors describe full schedule for ALT/AST monitoring. Due to logistic constraints, ALT and AST were only measured for the first 150 participantsIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskAuthors do not give reporting threshold for adverse events[@CD006404-bbs2-0007]MethodsRCT\
Duration: 1 year, 10 months. January 2007 to October 2008ParticipantsAdults and children with *P falciparum* malaria\
Number: 1271\
**Inclusion criteria**: age 3‐60 years; bodyweight 20 kg ‐ 90 kg; fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; anaemia (Hb \< 8 g/dL); severe vomiting; diarrhoea; pregnancy/lactation; other clinically significant disorder; hepatic impairment (undefined); renal impairment; antimalarial therapy in previous 2 weeks; investigational drug in previous 4 weeks; previous participation in study; allergy to study drugs\
**Diagnosis**: thick and thin film microscopy of *P falciparum* (asexual parasite density 1000 mm^3^‐ 100,000 mm^3^ blood)InterventionsRandomized in a 2:1 ratio to:\
pyronaridine‐artesunate combination (7.2: 2.4 mg/kg respectively) once a day for three days (N = 848)mefloqune ‐artesunate combination (6.2 to 12.5 mg/kg and 2.2 to 5.0 mg/kg respectively) once a day for three days (N = 423)OutcomesACPR\* day 28 PCR‐adjustedACPR day 28 unadjustedACPR day 42 PCR‐adjustedACPR day 42 unadjustedParasite clearance time (from first dose to aparasitaemia)†, ‡Fever clearance time (from first dose to apyrexia)†, ‡Proportion of patients with parasite clearance on days 1, 2, and 3, ‡Proportion of patients with fever clearance on days 1, 2, and 3, ‡Proportion of patients with gametocytes, ‡Gametocyte clearance time (not defined)‡Adverse events\
\*Adequate clinical and parasitological response rate\
†Two consecutive normal readings taken between 7 and 25 hours apart\
‡Not assessed in quantitative synthesis in this reviewNotesLocation: Asia (81%) and Africa (19%). Asia: Cambodia, India, Thailand, Vietnam. Africa: Bukina Faso, Ivory Coast, Tanzania\
Setting: local hospitals and health centres\
Malaria endemicity: high\
Resistance profile: in Cambodia, significantly extended parasite clearance times (for both treatment arms) were suggestive of *in vivo* resistance to artemisinin\
Source of funding: Medicines for Malaria Venture, Shin Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization scheduleAllocation concealment (selection bias)Low riskIndividually numbered treatment packs\
Randomization communicated by investigator to a third party who administered the correct amount of tabletsBlinding (performance bias and detection bias) All outcomesLow riskUnclear if patients blinded\
Outcome assessors blinded to group assignmentIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskProspectively registered. Report includes all prestated outcomes of interestOther biasLow riskSome authors employed by trial sponsors, but all authors assumed responsibility for reporting accuracyAdverse event monitoring (detection bias) Adverse EventsUnclear riskAuthors do not describe methods for monitoring adverse events, but includes biochemical monitoring\
Authors do describe time point of assessments in protocolIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskReport percentage of adverse events. Supplementary data table provided. Reports \"any cause\" adverse events if they occurred in \> 2% of patients. Reports \"treatment related\" adverse events if they occurred in \> 1% of patients. Does not report method of judging relation of adverse events to treatment[@CD006404-bbs2-0008]MethodsRCT\*\
Duration: 4 years, 4 months. 24 October 2011 to 01 February 2016\
\*Different arms at different study centres; therefore we requested disaggregated dataParticipantsAdults and children with *P falciparum* malaria\
Number: 4710 (2640 within pyronaridine‐artesunate subsection)\
**Inclusion criteria**: age \> 2 years\*; bodyweight ≥ 15 kg (decreased to ≥ 5 kg after review); fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; severe vomiting; severe diarrhoea; other clinically significant disorder including QTc ≥ 450 ms, active TB, jaundice and others; anaemia (Hb \< 70 g/dL); other febrile conditions; allergy to study drugs; antimalarial therapy in previous 2 weeks; investigational drug in previous 4 weeks; pregnancy/lactation; alcohol abuse; viral hepatitis/HIV; hepatic impairment (ALT \> 2 x ULN); renal impairment (1.5 x ULN)\
**Diagnosis**: positive microscopy for *Plasmodium* spp. (\> 0 to \< 200,000 parasites/μL blood)\
*\*For pyronaridine‐artesunate group, inclusion criteria changed during the study. (i) Beginning of the study, inclusion age of 15 years or older and bodyweight of 24 kg or over, (ii) after 20 retreatments, inclusion age of 2 years or older and bodyweight of 15 kg or over, and (iii) After 40 retreatments, inclusion age of at least 6 months with bodyweight of 5 kg or over*\
Children under 5: 344 (Pyr‐AS); 129 (AL); 249 (AS‐AQ)\
The total number of participants receiving at least one study treatment in each comparison are as below.\
Pyronaridine‐artesunate (n = 658) versus artemether‐lumefantrine (n = 665)Pyronaridine‐artesunate (n = 659) versus artesunate‐amodiaquine (n = 658)\
The breakdown of total participants receiving each treatment at each site is as below.\
Bobo‐Dioulasso, Burkina Faso: pyronardine‐artesunate (n = 212) versus artemether‐lumefantrine (n = 220)Ouagadougou, Burkina Faso: pyronaridine‐artesunate (n = 215) versus artesunate‐amodiaquine (n = 214)Bougoula, Mali: 1. PY‐AS (n = 214) versus AL (213); 2. PY‐AS (n = 94) versus artesunate‐amodiaquine (n = 98)Djoliba, Mali: pyronaridine‐artesunate (n = 87) versus AS‐AQ (n = 85)Kolle, Mali: 1. pyronaridine‐artesunate (n = 86) versus AL (87); 2. pyronaridine‐artesunate (n = 11) versus AS‐AQ (n = 11)Sotuba, Mali: 1. pyronaridine‐artesunate (n = 146) versus AL (145); 2. pyronaridine‐artesunate (n = 17) versus AS‐AQ (n = 17)Mafrinyah, Guinea: pyronaridine‐artesunate (n = 235) versus AS‐AQ (n = 233\
The total numbers of participants and numbers disaggregated by each site were obtained from the trial authors in response to a request for further information in May 2017InterventionsPyronaridine‐artesunate granules (60 mg:20 mg) or tablets (180 mg:60 mg) once‐daily for 3 days. Dose according to bodyweight: 5 kg ‐ 8 kg one sachet, 8 kg ‐ 15 kg 2 sachets, 15 kg ‐ 20 kg 3 sachets, 20 kg ‐ 24 kg one tablet, 24 kg ‐ 45 kg 2 tablets, 45 kg ‐ 65 kg 3 tablets, ≥ 65kg 4 tabletsArtemether‐lumefantrine tablets (20 mg/120 mg) twice daily for 3 days at recommended intervals. Dose according to bodyweight: 5 kg ‐ 15 kg one tablet, 15 kg ‐ 25 kg 2 tablets, 25 kg ‐ 35 kg 3 tablets, ≥ 35 kg 4 tabletsAmodiaquine‐artesunate tablets once‐daily for 3 days. Dose according to bodyweight: 5 kg ‐ 9 kg one 25 mg:67.5 mg tablet, 9 kg ‐ 18 kg one 50 mg:135 mg tablet, 18 kg ‐ 36 kg one 100 mg:270 mg tablet, ≥ 36 kg two 100 mg:270 mg tabletsDihydroartemisinin‐piperaquine\*\
\*Not compared against pyronaridine‐artesunate in this trialOutcomesTwo‐year incidence rate of all repeat malaria episodes (uncomplicated and complicated) irrespective of parasite species\*Crude and PCR‐corrected ACPR for *P falciparum* and crude ACPR for other *Plasmodium* species at days 28 and 42, irrespective of axillary temperature, without previous early treatment failure, late clinical failure, or late parasitological failureParasite clearance time (time from first dose until parasite negative, with aparasitaemia maintained for at least 48 hrs)\*Reinfection and recrudescence rates over 42 days\*Gametocyte density and carriage\*Difference in time to the second infection between treatments\*Difference in the mean interval between reinfection\*Adverse events\
\*Not assessed in quantitative synthesis in this reviewNotesLocation: West Africa (Burkina Faso, Guinea, Mali), conducted by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM).\
Setting: tertiary health facilities\
Malaria endemicity: high\
Resistance profile: not described\
Source of funding: European and Developing Countries Clinical Trial Partnership, Medicines for Malaria Venture, United Kingdom Medical Research Councils, Swedish International Development Co‐operation Agency, German Ministry for Education and Research, University Claude Bernard (France), University of Science Techniques and Technologies of Bamako, Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso), Institut de Recherche en Sciences de la Santé (Bobo‐ Dioulasso, Burkina Faso), and Centre National de Formation et de Recherche en Santé Rurale (Republic of Guinea)\
Follow‐up: 42 days active; 2 year passive***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization list for each site within each country was used; block size of twoAllocation concealment (selection bias)Low riskSealed, opaque, sequentially numbered envelopesBlinding (performance bias and detection bias) All outcomesLow riskOpen‐label: patients and investigators not blinded to treatment allocation\
Microscopists assessing parasite outcomes masked to treatment allocationIncomplete outcome data (attrition bias) All outcomesLow riskReasons provided for all withdrawals across study arms. Withdrawal numbers small and balanced across the intervention arms with reasons for withdrawal similar between groupsSelective reporting (reporting bias)Low riskAll outcomes reported as listed in the trial register, however day 63 outcomes are not reportedOther biasLow riskSome authors employed by trial sponsors, but all authors assumed responsibility for reporting accuracyAdverse event monitoring (detection bias) Adverse EventsLow riskAuthors report that physical examinations made and adverse events recorded at all assessments. Describes ECG and biochemistry monitoring schedule. Used Medical Dictionary for Regulatory Activities (MedDRA)Incomplete adverse event reporting (reporting bias) Adverse eventsLow riskAuthors enumerate adverse events clearly, and report events of interest. Provide supplementary tables. We were unable to extract adverse events by study site.[@CD006404-bbs2-0009]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 232InterventionsPyronaridine‐artesunate (n = 212)Artemether‐lumefantrine (n = 220)Outcomes‐NotesLocation: Bobo, Burkina Faso***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0010]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 619InterventionsComparison 1\
Pyronaridine‐artesunate (n = 214)Artemether‐lumefantrine (n = 213)\
Comparison 2\
Pyronaridine‐artesunate (n = 94)Amodiaquine‐artesunate (n = 98)Outcomes‐NotesLocation: Bougoula, Mali***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0011]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 172InterventionsPyronaridine‐artesunate (n = 87)Amodiaquine‐artesunate (n = 85)Outcomes‐NotesLocation: Djoliba, Mali***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0012]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 195InterventionsComparison 1\
Pyronaridine‐artesunate (n = 86)Artemether‐lumefantrine (n = 87)\
Comparison 2\
Pyronaridine‐artesunate (n = 11)Amodiaquine‐artesunate (n = 11)Outcomes‐NotesLocation: Kolle, Mali***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0013]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 468InterventionsPyronaridine‐artesunate (n = 235)Amodiaquine‐artesunate (n = 233)Outcomes‐NotesLocation: Mafrinyah, Guinea***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0014]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 429InterventionsPyronaridine‐artesunate (n = 215)Amodiaquine‐artesunate (n = 214)Outcomes‐NotesLocation: Ouagadougou, Burkina Faso***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0015]MethodsRCT\* ‐ represents disaggregated data from [@CD006404-bbs2-0008] (see above)ParticipantsNumber receiving at least one study treatment: 325InterventionsComparison 1\
Pyronaridine‐artesunate (n = 146)Artemether‐lumefantrine (n = 145)\
Comparison 2\
Pyronaridine‐artesunate (n = 17)Amodiaquine‐artesunate (n = 17)Outcomes‐NotesLocation: Sotuba, Mali***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRepresents disaggregated data from [@CD006404-bbs2-0008] (see above)Allocation concealment (selection bias)Low risk‐Blinding (performance bias and detection bias) All outcomesLow risk‐Incomplete outcome data (attrition bias) All outcomesLow risk‐Selective reporting (reporting bias)Low risk‐Other biasLow risk‐Adverse event monitoring (detection bias) Adverse EventsLow risk‐Incomplete adverse event reporting (reporting bias) Adverse eventsLow risk‐[@CD006404-bbs2-0016]MethodsRCTParticipantsAdults and children with *P vivax* malaria\
Number: 30InterventionsPyronaridine‐artesunate tablets (180 mg:60 mg)ChloroquineOutcomesCure rate day 14\*Cure rates day 28 and 42\*Fever clearance time\*Parasite clearance time\*Proportions aparasitaemic on days 1, 2, and 3\*Adverse events\
\*Not assessed in quantitative synthesis in this reviewNotesLocation: Korea\
Setting: not known\
Malaria endemicity: unstable\
Resistance profile: not described\
Source of funding: not known\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPatients assigned in ascending order a randomization number according to order recruitedAllocation concealment (selection bias)Low riskSealed opaque envelopesBlinding (performance bias and detection bias) All outcomesLow riskPatients and investigators blindedIncomplete outcome data (attrition bias) All outcomesLow riskData available for 14 of 15 patients in pyronardine‐artesunate arm, and 15 of 15 patients in chloroquine armSelective reporting (reporting bias)Low riskAuthors provided all data requestedOther biasUnclear riskAuthors from pharmaceutical company manufacturing pyronardine‐artesunateAdverse event monitoring (detection bias) Adverse EventsLow riskFull schedule of safety monitoringIncomplete adverse event reporting (reporting bias) Adverse eventsLow riskAuthors provided all data requested[@CD006404-bbs2-0017]MethodsRCT\
Duration: 1 year, 3 months. January 2007 to April 2008ParticipantsAdults and children with *P falciparum* malaria\
Number: 1272\
**Inclusion criteria**: age 3‐60 years; bodyweight 20 kg ‐ 90 kg; fever or history of fever within 24 hours\
**Exclusion criteria**: severe/complicated malaria; mixed *Plasmodium* infection; malnutrition; anaemia (Hb \< 8 g/dL); severe vomiting; severe diarrhoea; other clinically significant disorder; hepatic impairment (limit not stated); renal impairment; other febrile conditions; viral hepatitis/HIV; electrolyte imbalance; allergy to study drugs; antimalarial therapy in previous 2 weeks, investigational drug in previous 4 weeks; taking any drug metabolized by cytochrome enzyme CYP2D6; previous participation in pyronaridine‐artesunate studies; pregnancy/lactation\
**Diagnosis**: microscopy (asexual parasite density 1000 µL to 100,000/µL blood)InterventionsRandomized in a 2:1 ratio to:\
pyronaridine‐artesunate tablets (180 mg:60 mg) once‐daily for 3 days. Dose according to bodyweight: 20 kg ‐ 25 kg one tablet, 26 kg ‐ 45 kg 2 tablets, 45 kg ‐ 65 kg 3 tablets, ≥ 65kg 4 tablets (N = 849)Artemether‐lumefantrine tablets (20 mg/120 mg) twice daily for 3 days at recommended intervals. Dose according to bodyweight: 20 kg ‐ 25 kg 2 tablets, 25 kg ‐ 35 kg 3 tablets, ≥ 35 kg 4 tabletsOutcomesACPR\* day 28 PCR‐adjustedACPR day 28 unadjustedACPR day 42 PCR‐adjustedACPR day 42 unadjustedParasite clearance time (from first dose to aparasitaemia)†, ‡Fever clearance time (from first dose to apyrexia)†, ‡Proportion of patients with parasite clearance on days 1, 2, and 3, ‡Proportion of patients with fever clearance on days 1, 2, and 3, ‡Gametocyte density, ‡Adverse events (including laboratory and ECG abnormalities)\
\*Adequate clinical and parasitological response rate\
†Two consecutive normal readings taken between 7 and 25 hours apart\
‡Not assessed in quantitative synthesis in this reviewNotesLocation: Africa (n = 1080, 85%) and Asia (n = 192, 15%). Africa: DRC, The Gambia, Ghana, Kenya, Mali, Mozambique, Senegal. Asia: Indonesia, the Phillipines\
Setting: local hospitals and clinics\
Malaria endemicity: high\
Resistance profile: not described\
Funding: Medicines for Malaria Venture, Shin Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
Follow‐up: 42 days***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated randomization schedule. Block randomization of 9 by study centreAllocation concealment (selection bias)Low riskIndividually numbered treatment packs\
Randomization communicated by investigator to a third party who administered the correct amount of tablets, and who was not involved in clinical assessmentBlinding (performance bias and detection bias) All outcomesLow riskPatients blinded: artemether‐lumefantrine placebo dosed twice daily to maintain blinding. Food not required for artemether‐lumefantrine dosing to retain blinding\
Outcome assessors blinded to group assignmentIncomplete outcome data (attrition bias) All outcomesLow riskReport lists reasons for attrition and exclusionsSelective reporting (reporting bias)Low riskProspectively registered. Report includes prestated outcomes of interest. Day 42 efficacy outcomes and gametocyte counts not listed in trial registration document; listed in the report as exploratoryOther biasUnclear riskSponsors designed the trial, were responsible for data collection and analysis, and developed the report; all authors had access to trial data\
Participants on artemether‐lumefantrine were not expected to take medication after food; unclear if this reduced bioavailability of lumefantrineAdverse event monitoring (detection bias) Adverse EventsLow riskReport that adverse events recorded during treatment and at all follow‐up visitsIncomplete adverse event reporting (reporting bias) Adverse eventsUnclear riskAuthors report all‐cause adverse events as percentages. Report table only includes adverse events occurring in ≥ 5% (or ≥ 1% if judged to be drug related). Authors explain method for determining relation to study drug[^11]

Characteristics of excluded studies \[ordered by study ID\] {#CD006404-sec2-0024}
===========================================================

StudyReason for exclusion[@CD006404-bbs2-0018]Quasi‐RCT. Randomized according to order of admission[@CD006404-bbs2-0019]Quasi‐RCT. Odd and even numbers used for allocation[@CD006404-bbs2-0020]RCT: conducted in people with complicated falciparum malaria[@CD006404-bbs2-0021]Trial registration (ACTRN12610000913077) planned to use pyronaridine‐artesunate, but not available due to concerns over hepatotoxicity at time of trial[@CD006404-bbs2-0022]Not a RCT: single‐arm observational study[@CD006404-bbs2-0023]Not a RCT: clinical trial of two doses of pyronaridine monotherapy with group given second dose recruited after results of first dose were analysed[@CD006404-bbs2-0024]RCT: phase II dose ranging trial[@CD006404-bbs2-0025]Not a RCT: phase II dose ranging study[@CD006404-bbs2-0026]Not a RCT: open‐label dose‐escalation study[@CD006404-bbs2-0027]Not a RCT: pooled analysis[^12]

For this update, Joseph Pryce (JP) and Paul Hine (PH) extracted data from all studies, and verified characteristics of studies and previous 'Risk of bias\' assessments. PH rewrote the [Background](#CD006404-sec1-0002){ref-type="sec"}, [Methods](#CD006404-sec1-0004){ref-type="sec"}, [Discussion](#CD006404-sec1-0006){ref-type="sec"}, and [Authors\' conclusions](#CD006404-sec1-0007){ref-type="sec"}, with contributions from JP. PH and JP completed the analysis, 'Summary of findings\' tables, and results. Both review authors read and approved the final manuscript.
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Not applicable.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^Downgraded by 1 for serious indirectness: the trials included adults and children and had sites in Africa and Asia. However across the trials, only 115 children and 0 adults were randomized to pyronaridine‐artesunate in Asia. Further adequately powered studies in adults and children in Asia would be needed to fully apply this result. ^b^Downgraded by 1 for serious imprecision: the CI includes both no effect and clinically significant effect. ^c^Certainty of the evidence grade differs from the 2014 review version due to additional data: the previous review reported no substantial difference between PY‐AS and AL in reference to this outcome and therefore did not downgrade for imprecision. In this update we report a reduced rate in the PY‐AS arm. Because we concluded that there may be a difference, we necessarily downgraded for the imprecision. ^d^Certainty of the evidence grade differs from the 2014 review version due to additional data: the introduction of more data increased the heterogeneity between the included trials. ^e^Downgraded by 1 for serious inconsistency: there was quantitative heterogeneity between studies. ^f^Downgraded by 2 for very serious imprecision: the low number of events recorded in the studies is insufficient for confidently estimating the effect size. ^g^Downgraded by 1 for serious imprecision: the CI is wide and includes a clinically significant effect, and almost no effect. ^h^Downgraded by 1 for serious inconsistency: there was qualitative heterogeneity between studies.

[^3]: ^a^Serious adverse events data were not available disaggregated by site to allow inclusion in this comparison. ^b^Downgraded by 1 for serious indirectness: the data are drawn from one study, conducted in six sites in three countries in West Africa. Further studies in Asia would be needed to fully apply this result. ^c^Downgraded by 1 for serious imprecision: the CI is large and includes both no effect and clinically important effects. ^d^Downgraded by 1 for serious imprecision: the effect estimate is close to no effect, but the CI is wide. ^e^Downgraded by 1 for serious imprecision: the low number of events recorded in the study is insufficient for confidently estimating the effect size. However, aggregate analysis of ALT increase across different comparator drugs provides indirect evidence that the point estimate may be accurate. ^f^Downgraded by 2 for very serious imprecision: the CI is very large and includes both no effect and clinically important effects.

[^4]: ^a^Downgraded by 1 for serious indirectness: of the 1271 children and adults aged greater than 5 years enrolled in this trial, 81.3% (1033) were enrolled and treated in trial sites in Asia (Cambodia, India, Thailand, and Vietnam), and only 18.7% (237) in Africa (Burkina Faso, Ivory Coast, and Tanzania). Further studies in African children are necessary to fully apply this result. ^b^Downgraded by 1 for serious imprecision: the CI is large and includes both no effect and clinically important effects. ^c^Certainty of the evidence grade differs from the 2014 review version due to additional data: the previous review reported no substantial difference between PY‐AS and MQ+AS in reference to this outcome and therefore did not downgrade for imprecision. In this update we report a reduced rate in the PY‐AS arm. Because we concluded that there may be a difference, we necessarily downgraded for the imprecision. ^d^Certainty of the evidence grade differs from the 2014 review version due to alterations in the data extraction protocol: the CI has become less precise, and our decision has greater consistency with other outcome certainty grades. ^e^Downgraded by 1 for serious imprecision: the low number of events recorded in the study is insufficient for confidently estimating the effect size. However, aggregate analysis of ALT increase across different comparator drugs provides indirect evidence that the point estimate may be accurate. ^f^Downgraded by 2 for very serious imprecision: the CI is very large and includes both no effect and clinically important effects.

[^5]: ^a^Only adverse event outcomes were considered for this comparison. ^b^A comparison of pyronaridine‐artesunate versus other antimalarials for frequency of ECG abnormalities is reported in [Table 13](#CD006404-tbl-0013){ref-type="table"}. ^c^The length of follow‐up varies between specific studies. Follow‐up times are reported for individual studies in the '[Characteristics of included studies](#CD006404-sec2-0023){ref-type="sec"}\' tables. ^d^Downgraded by 1 for serious imprecision: the CI includes both no effect and clinically important effects. ^e^Not downgraded: although the CI is wide, there were few events. ^f^Downgraded by 1 for serious indirectness: only 232 children aged less than five years were included in this study.

[^6]: Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.

[^7]: Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase.

    ^a^Study authors judged as unrelated to drug. ^b^Study authors judged as unlikely related to drug. ^c^Study authors judged as treatment‐related. ^d^Authors do not report the nature of the serious adverse events they judged to be unrelated to drug. Some of the listed events in the comparator groups may have occurred in comparisons with dihydroartemisinin‐piperaquine, but we were unable to extract data in relation to this.

[^8]: Abbreviations: AL: artemether‐lumefantrine; PY‐AS: pyronaridine‐artesunate.

[^9]: Abbreviations: MQ+AS: mefloquine plus artesunate; PY‐AS: pyronaridine‐artesunate.

[^10]: ^a^*P vivax* participants only. ^b^Pyronaridine alone used as study drug.

[^11]: Abbreviations: ACPR: adequate clinical and parasitological response; ALT: alanine aminotransferase; AST: aspartate transaminase; ECG: electrocardiogram; Hb: haemoglobin; MMV: Medicines for Malaria Venture; PCR: polymerase chain reaction; QT: QT interval on electrocardiogram; QTc: corrected QT interval on electrocardiogram; RCT: randomized controlled trial; ULN: upper limit of normal.

[^12]: Abbreviations: RCT: randomized controlled trial.
